Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Ac t (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑

The aggregate market value of the common stock held by non-affiliates of the registrant as of December 31, ~~2020~~2021 was approximately ~~$70,780,000~~$91,856,000 based upon the closing price of the registrant’s common stock, as reported on the NYSE American, on such date.

There were ~~8,559,109~~8,475,438 shares of the registrant’s common stock outstanding as of August ~~20, 2021.~~23, 2022.

Portions of the Definitive Proxy Statement for the registrant’s Fiscal ~~2021~~2023 Annual Meeting of Shareholders, to be filed within 120 days of June 30, ~~2021,~~2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Statements contained in this Annual Report on Form 10-K that are not statements of historical fact should be considered forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, ~~(the “Securities Act”),~~ and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, but are not limited to, statements regarding: the expected impact of the COVID-19 pandemic on our business; our business strategy, including our intended level of investment in research and development ~~(“R&D”)~~ and marketing activities; our expectations with respect to earnings, gross margins and sales growth, industry relationships, marketing strategies and international sales; estimated sizes of markets into which our products are or may be sold; our business strengths and competitive advantages; our ability to grow additional sales distribution channels; our intent to retain any earnings for use in operations rather than paying dividends; our expectation that our products will continue to qualify for reimbursement and payment under government and private insurance programs; our intellectual property plans and practices; the expected impact of applicable regulations on our business; our beliefs about our manufacturing processes; our expectations and beliefs with respect to our employees and our relationships with them; our belief that our current facilities are adequate to support our growth plans; our expectations with respect to ongoing compliance with the terms of our credit facility; our expectations regarding the ongoing availability of credit and our ability to renew our line of credit; enhancements to our products and services; expected excise tax exemption for the SmartVest ~~Airway Clearance~~ System; and our anticipated revenues, expenses, capital requirements and liquidity. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” ~~“goal,”~~ “intend,” “may,” “ongoing,” “plan,” “potential,” “project,” ~~“should,~~“goal,” “target,” “should,” “will,” “would,” and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Although we believe these forward-looking statements are reasonable, they involve risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry’s actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by the forward-looking statements.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited ~~to:~~to, the following:

This list of factors is not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect on us and our results of operations. Therefore, you should consider these risk factors with caution and form your own critical and independent conclusions about the likely ~~effects~~effect of these risk factors on our future performance. Forward-looking statements speak only as of the date on which the statements are made, and we undertake no obligation, and expressly disclaim any such obligation, to update any forward-looking statement for any reason other than as required by law, even if new information becomes available or other events occur in the future. You should carefully review the disclosures and the risk factors described in this and other documents we file from time to time with the Securities and Exchange Commission (the “SEC”)~~, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.~~. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth herein.

Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest^® Airway Clearance System (“SmartVest System”) and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation (“HFCWO”) treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.

We employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional durable medical equipment (“DME”) channel and capture both the manufacturer and distributor margins. We also sell our products in the acute care setting for patients in a post-surgical or intensive care unit, or who were admitted for a lung infection brought on by compromised airway clearance. Electromed was incorporated in Minnesota in 1992. Our common stock is listed on the NYSE American under the ticker symbol “ELMD.”

The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy. The SmartVest System generates HFCWO, an airway clearance therapy. One factor of respiratory health is the ability to clear secretions from airways. Impaired airway clearance, when mucus cannot be expectorated, may result in labored breathing and/or inflammatory and immune systems boosting mucus production that invites bacteria trapped in stagnant secretions to cause infections. Studies show that HFCWO therapy is as effective an airway clearance method for patients who have compromised pulmonary function as traditional chest physical therapy (“CPT”) administered by a respiratory therapist.¹ However, HFCWO can be self-administered, relieving a caregiver of participation in the therapy, and eliminating the attendant cost of an in-home care provider. We believe that HFCWO treatments are cost-effective primarily because they reduce a patient’s risk of respiratory infections and other secondary complications that are associated with impaired airway clearance and often result in costly hospital visits and repeated antibiotic use.

The SmartVest System is designed for patient comfort and ease of use which promotes adherence to prescribed treatment schedules, leading to improved airway clearance, patient outcomes and quality of life, and a reduction in healthcare utilization. We offer a broad range of garments, referred to as vests and wraps, in sizes for children and adults that allow for tailored fit. User-friendly controls allow patients to administer their daily therapy with minimal or no assistance. Our direct product support services provide patient and clinician education, training, and follow-up to ensure that the product is integrated into each patient’s daily treatment regimen. Additionally, our reimbursement department assures we are working on behalf of the patient by processing their physician paperwork, providing clinical support and billing the applicable insurance provider. We believe that the advantages of the SmartVest System and the Company’s customer services to the patient include:

¹Nicolini A, et al. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulmonary ~~Medicine~~Medicine. 2013;13(21). ~~2013;13(21).~~

Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis(“ALS”). Our products are sold into the home health care market and the acute care setting for patients in a post-surgical or intensive care unit, or who were admitted for a lung infection brought on by compromised airway clearance. Accordingly, our sales points of contact include adult pulmonology clinics, cystic fibrosis centers, neuromuscular clinics and hospitals.

We have received clearance from the U.S. Food and Drug Administration (“FDA”) to market the SmartVest System to promote airway clearance and improve bronchial drainage. In addition, Electromed is certified to apply the Conformité Européenne (“European Conformity” or “CE”) marking for HFCWO device sales in all European Union member countries and approved for HFCWO device sales in other, select international countries. The SmartVest System is available only with a physician’s prescription.

The SmartVest System is currently available in one model – SQL^® – which is sold into home care and hospital markets. ~~As previously announced, we discontinued new patient and hospital market shipments of the SmartVest SV2100 model of the SmartVest System on July 1, 2021.~~ We will continue to support and service ~~the~~earlier SmartVest ~~SV2100 model~~models pursuant to the applicable product warranty.

As part of our growth strategies, we periodically evaluate opportunities involving products and services, especially those that may provide value to the respiratory homecare and institutional market. To that end, we made meaningful progress in the development ~~for~~of our next generation SmartVest System during our fiscal year ended June 30, ~~2021~~2022 (“fiscal ~~2021”~~2022”) and estimate launching such device and completing the corresponding FDA 510(k) clearance process in the first half of our fiscal year ending June 30, 2023 (“fiscal 2023”).

The SmartVest SQL System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment. The SmartVest SQL is designed for maximum comfort and lifestyle convenience, so patients can readily fit therapy into their daily routines. The SmartVest SQL was designed to be significantly smaller, quieter, and lighter than its predecessor, and offers features that make it easier to use and enable greater patient freedom.

In June 2017, we launched the SmartVest SQL with SmartVest Connect^® wireless technology, a personalized HFCWO therapy management portal for patients with compromised pulmonary function. In March 2020, we launched the SmartVest Connect app for both the iOS and Android operating systems. The SmartVest Connect app securely connects to the SmartVest SQL System through Bluetooth™ technology. This interface allows patients and healthcare teams to track therapy in real-time and collaborate on care decisions to improve therapy adherence and patient outcomes. SmartVest Connect is available to pediatric and cystic fibrosis patients, and targeted adult pulmonary clinics using a Bluetooth-enabled SmartVest SQL System.

We market the Single Patient Use (“SPU”) SmartVest and SmartVest Wrap^® to health care providers in the acute care setting. Hospitals issue the SPU SmartVest or SmartVest Wrap to an individual patient for managing airway clearance. Both SPU products provide full coverage oscillation and facilitate continuity of care because they introduce the patient to our product and may encourage use of the SmartVest System for home care, which can be provided to patients with a chronic condition upon discharge.

We estimate the total served U.S. market for HFCWO ~~in 2019 was between~~has returned to pre-pandemic levels and is estimated at approximately $220 million to $240 million, with growth in HFCWO adoption at approximately 5% based on independent third-party market research. We believe the market for HFCWO is continuing to expand due to an aging population, higher incidence of chronic lung disease, ~~and~~ growing awareness by physicians of diseases and conditions for which patients can benefit from using HFCWO therapy,, and treatments moving to lower cost home care settings. Indications for when HFCWO may be prescribed are not specific to any one disease. A physician may elect to prescribe HFCWO when ~~he or she~~such individual believes the patient will benefit from improved airway clearance and external chest manipulation is the treatment of choice to enhance mucus transport and improve bronchial drainage.

The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and ALS. We believe that bronchiectasis represents the fastest growing diagnostic category and greatest potential for HFCWO growth in the United ~~States.~~States exhibiting an 8.7% increase in patients diagnosed between 2000 and 2007⁹. Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi. The condition is associated with recurrent lower respiratory infections, inflammation, reduction in pulmonary function, impaired respiratory secretion clearance, increased hospitalizations and medication use, and increased morbidity and mortality.

We are driven to make ~~life’s~~life's important moments possible, one breath at a time, by leading the HFCWO therapy market in clinical evidence that supports the therapeutic imperative of clearing excess mucus from the lungs. Electromed iscontinues to add to the ~~only~~body of evidence in support of HFCWO ~~therapy company~~ with multiple published clinical outcome studies demonstrating a significant improvement in quality of life and reduction in exacerbation rates, hospitalizations, emergency department visits, and antibiotic prescriptions in bronchiectasis patients using the SmartVest System. This includes the most recent clinical study, a 2022 publication in the American Journal of Respiratory and Critical Care Medicine reviewing outcomes among non-cystic fibrosis bronchiectasis patients with HFCWO Therapy.^2-52-6 ~~Leading in~~Generating additional clinical evidence to further support the SmartVest System as a preferred treatment for bronchiectasis patients will remain a focus for us in ~~our~~ fiscal ~~year ending June 30, 2022 (“fiscal 2022”),~~2023, with two clinical studies ~~currently enrolling.~~in progress. The first such clinical study is a prospective, multi-center bronchiectasis outcomes study utilizing SmartVest therapy, and the second is a post surveillance study with chronic obstructive pulmonary disease ~~(“COPD”~~("COPD") and bronchiectasis patients prescribed SmartVest utilizing quality of life questionnaires to measure outcomes prior to therapy and at two intervals following initiation of the therapy.

We believe that bronchiectasis is under recognized and underdiagnosed but is experiencing a surge in clinical interest and awareness, including the relationship to COPD, commonly referred to as bronchiectasis COPD overlap syndrome. The overlap of bronchiectasis and COPD increases exacerbations and hospitalizations, reduces pulmonary function, and increases mortality. Several recent studies have estimated prevalence of bronchiectasis, which we believe are helpful for estimating a range of the overall market size.

These studies indicate a wide range of potential prevalence of bronchiectasis patients in the United States. We also believe that it is difficult to estimate from these studies which patients will need or benefit from HFCWO. ~~The U.S. BRR indicated 15%~~Internal company estimates derived from 2020 analysis of the ~~patients included in~~IQVIA PharMetrics Plus database, one of the ~~registry were prescribed~~largest US health plan databases of adjudicated integrated medical and pharmacy claims, indicate a 15% to 20% penetration of HFCWO ~~as part of their treatment plan. Using that study data, we estimate that,~~ within the diagnosed ~~Medicare~~Bronchiectasis population¹⁵. By conservatively assessing the market size in relation to the clinical studies cited above, we calculate that current HFCWO adoption may account for only 90,000 patients of ~~515,000, approximately 15% or 77,000 have been prescribed HFCWO.~~the 500 to 600 thousand currently diagnosed and treatable patients (see Figure 1 below). We believe that bronchiectasis is underdiagnosed in the U.S. based on clinical study ~~evidence.~~and epidemiology evidence with an even greater number of patients that could potentially benefit from diagnosis and treatment. We ~~also~~ believe that HFCWO is under prescribed for bronchiectasis ~~patients. By applying approximately 15%~~patients resulting in a large, underpenetrated US market opportunity and growth potential for HFCWO penetration of diagnosed Medicare patients to the Weycker clinical study cited above to the estimated 4.2 million prevalence of bronchiectasis in the U.S., we derived that the HFCWO opportunity may be 630,000 forecasted units (see Figure 1 below).therapy.

~~Estimated HFCWO Market Opportunity - Bronchiectasis Patients (U.S.) – Figure 1~~

The heightened awareness of bronchiectasis speaks to the growing body of clinical evidence supporting treatments to improve symptoms and manage disease progression. In 2019, an observational comparative retrospective cohort study published in ~~BMC Pulmonary Medicine~~ ~~evaluated the efficacy of a treatment algorithm in 65 patients with radiographic and symptom confirmed bronchiectasis, centered on initiation of HFCWO therapy with the SmartVest System.~~⁵ Patients were treated per the algorithm if they reported greater than two exacerbations in the previous year and symptoms, including chronic cough, sputum production, or dyspnea. Results show that at one-year: exacerbations requiring hospitalization and antibiotic use were significantly reduced and mean-forced expiratory volume₁ ~~remained stable post enrollment, suggesting early initiation of HFCWO therapy may slow the otherwise normal progression of the disease.~~

²Sievert C, et al. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy Journal. 2016;11(4): 34–38.

³Sievert C, et al. Cost-Effective Analysis of Using High Frequency Chest Wall Oscillation (HFCWO) in Patients with Non-Cystic Fibrosis Bronchiectasis. Respiratory Therapy Journal. 2017;12(1): 45–49.

⁴Sievert C, et al. Incidence of Bronchiectasis-Related Exacerbation Rates After High Frequency Chest Wall Oscillation (HFCWO) Treatment — A Longitudinal Outcome-Based Study. Respiratory Therapy Journal. 2018;13(2): 38–41.

⁵Powner J, et al. Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis. BMC Pulmonary Medicine. 2019;19(82).

⁶~~Aksamit T, et al.~~DeKoven M, Mandia K, DeFabis N, Chen J, Ruscio A. Patient Characteristics, Healthcare Resource Utilization And Outcomes Among Non-Cystic Fibrosis Bronchiectasis ~~Research Registry C. Adult~~ Patients With ~~Bronchiectasis: A First Look at the~~High Frequency Chest Wall Oscillation (HFCWO) Therapy. American Journal of Respiratory and Critical Care Medicine. 2022. Vol 205:A3090

⁷Weycker D, Hansen G, Seifer F. Prevalence and incidence of noncystic fibrosis bronchiectasis among US ~~Bronchiectasis Research Registry.~~adults in 2013. ~~Chest~~Chronic Respiratory Disease.. 2017;~~151:982-92.~~ 14(4):377-384.

⁷~~Patel I.S., et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.~~ ~~Am J Respir Crit Care Med~~~~. 2004;170:400-7.~~

⁸~~O’Brien C, et al. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care.~~ ~~Thorax~~~~. 2000;55:635-42.~~

⁹~~Bafadhel M, et al. The role of CT scanning in multidimensional phenotyping of COPD.~~ ~~Chest~~~~. 2011;140:634-42.~~

¹⁰~~Chalmers J. and Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults.~~ ~~NPJ Prim Care Respir Med~~~~. 2017;27:18.~~

¹¹Henkle E, et al. Characteristics and Health-care Utilization History of Patients with Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest. 2018;154(6), 1311–1320.

¹²⁹Seitz A, et al. Trends in Bronchiectasis Among Medicare Beneficiaries in the United States, 2000 to 2007. Chest. 2012;142(2), 432–439.

¹⁰Aksamit T, et al. Bronchiectasis Research Registry C. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. 2017;151:982-92.

¹¹Patel I.S., et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:400-7.

¹²O’Brien C, et al. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635-42.

¹³~~Weycker D, Hansen G, Seifer F. Prevalence~~Bafadhel M, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011;140:634-42.

¹⁴Chalmers J. and ~~incidence~~Sethi S. Raising awareness of ~~noncystic fibrosis~~ bronchiectasis ~~among US adults~~ in ~~2013.~~primary care: overview of diagnosis and management strategies in adults. ~~Chronic Respiratory Disease.~~NPJ Prim Care Respir Med. 2017; ~~14(4):377-384.~~27:18.

¹⁵Internal company estimates derived from IQVIA 2018 PharMetrics Plus Database

Estimated HFCWO Market Opportunity - Bronchiectasis Patients (U.S.) – Figure 1

The heightened awareness of bronchiectasis speaks to the growing body of clinical evidence supporting treatments to improve symptoms and manage disease progression.

Our sales and marketing efforts are focused on ~~building market awareness and acceptance~~driving adoption of our products and services with physicians, clinicians, patients, and third-party ~~payers.~~payers and building market awareness to the benefits of HFCWO for treatment of bronchiectasis. Because the sale of the SmartVest System requires a ~~physician’s~~physician's prescription, we market to physicians and health care providers as well as directly to patients. The majority of our revenue comes from domestic home care sales through a physician referral model. We have established our own domestic sales force and support network, which we believe is able to provide superior education, support and training to our customers.

Our direct U.S. sales force works with physicians and clinicians, primarily pulmonologists, in defined territories to help them understand our products and services and the value they provide to their respective patients. As of June 30, ~~2021,~~2022, we had 4652 field sales employees, including ~~five~~six regional sales managers, 3743 clinical area managers (“CAMs”) and ~~two~~three clinical educators. We also have developed a network of approximately 250 respiratory therapists and health care professionals across the U.S. to assist with in-home SmartVest System patient training on a non-exclusive, independent contractor basis. ~~Virtual patient trainings are also available upon patient request.~~ These independent contractors are credentialed by the National Board for Respiratory Care as either Certified Respiratory Therapists or Registered Respiratory ~~Therapists.~~Therapists and provide national coverage to an internal team of Registered Respiratory Therapists dedicated to supporting SmartVest patients. Additionally, Electromed employs a team of reimbursement specialists dedicated to managing insurance and payer relations and supporting prescribers and patients in navigating financial considerations. The availability of reimbursement is an important consideration for health care professionals and patients. Because our product has an assigned Healthcare Common Procedure Coding System (“HCPCS”) code, a claim can be billed for reimbursement using that code. We must demonstrate the effectiveness of our products to public and private insurance providers. The availability of reimbursement exists primarily due to an established HCPCS code for HFCWO. A HCPCS code is assigned to services and products by the Centers for Medicare and Medicaid Services (“CMS”).

We generate sales ~~leads~~interest through multiple channels that include visits to pulmonology clinics and medical centers, participation in medical conferences, maintenance of industry contacts to increase the visibility and acceptance of our products by physicians and health care professionals, participation with patient organizations such as the Cystic Fibrosis Foundation, as well as through a focus on increasing patients by word of mouth and traffic to our website and social media channels. We continue to evaluate opportunities to offer the SmartVest System through selected Home Medical Equipment (“HME”) distributors. We ~~entered into~~maintain agreements with ~~four~~three HME distributors, one national and ~~three~~two regional, to distribute and sell the SmartVest System in the United States home care market. We expect to continue our direct sales channel as our primary homecare revenue source. Sale of the SmartVest System through HME distributors began in targeted geographies in first quarter of our fiscal year ended June 30, 2020 (“fiscal 2020”), and we had approximately $563,000 of revenue generated through these channels during fiscal 2021.

We believe that the addition of our HME distribution network expands our access to physicians and hospitals in certain areas of the United States and supports our other growth strategies. In addition, we place advertisements in leading medical magazines and journals.

Additionally, because the availability of reimbursement is an important consideration for health care professionals and patients, we must also demonstrate the effectiveness of our products to public and private insurance providers. The availability of reimbursement exists primarily due to an established Healthcare Common Procedure Coding System (“HCPCS”) code for HFCWO. A HCPCS code is assigned to services and products by the Centers for Medicare and Medicaid Services (“CMS”). Because our product has an assigned HCPCS code, a claim can be billed for reimbursement using that code.

Approximately ~~1.8%~~1.3% and ~~2.2%~~1.8% of our net revenues were from sales outside of the U.S. in our fiscal 2022 and our fiscal year ended June 30, 2021 ~~and~~ (“fiscal ~~2020,~~2021”), respectively. We sell our products outside of the U.S. primarily through independent distributors specializing in respiratory products. Through June 30, ~~2021,~~2022, the majority of our distributors operated in exclusive territories. Our principal distributors are located in Europe, the Arab states of the Persian Gulf, Southeast Asia, South America and Central America. Units are sold at a fixed contract price with payments made directly from the distributor, rather than being tied to reimbursement rates of a patient’s insurance provider as is the case for domestic sales. Our sales strategy outside of the U.S. is to maintain our current distributors with less emphasis on contracting with new distributors.

In the U.S., individuals who use the SmartVest System generally rely on third-party payers, including private payers and governmental payers such as Medicare and Medicaid, to cover and reimburse all or part of the cost of using the SmartVest System. Our home care revenue comes from reimbursement from commercial ~~payors,~~payers, Medicare, Medicaid, Veterans Affairs and direct patient payments. Reimbursement for HFCWO therapy and the SmartVest System varies among public and private insurance providers.

A key strategy to grow sales is achieving world class customer service and support for our patients and clinicians and increasing the number of covered lives across a broad payer market. We do this with an established and effective reimbursement department working on behalf of the patient by processing physician paperwork, seeking insurance authorization and processing claims. The skill and knowledge gained and offered by our reimbursement department is an important factor in building our revenue and serving patients’ financial interests. Our payment terms generally allow patients to acquire the SmartVest System over a period of one to 15 months, which is consistent with reimbursement procedures followed by Medicare and other third parties. The payment amount we receive for any single referral may vary based on a number of factors, including Medicare and third-party reimbursement processes and policies. The patient retains the risk of reimbursement to the Company in the event of non-payment by third-party payers. The reimbursement department includes the payer relations function working directly with all payer types to increase the covered lives for the SmartVest System with national and regional private insurers and applicable state and federal government entities as well as to maintain all of the current licenses with state and federal government and payer contracts.

Our SmartVest System is reimbursed under HCPCS code E0483. Currently, the Medicare total allowable amount of reimbursement for this billing code is approximately $13,000. The allowed amount for state Medicaid programs ranges from approximately $8,000 to $13,000, which is similar to commercial payers. Actual reimbursement from third-party payers can vary and can be significantly less than the full allowable amount. Deductions from the allowable amount, such as co-payments, deductibles and/or maximums on durable medical equipment, decrease the reimbursement received from the third-party payer. Collecting a full allowable amount depends on our ability to obtain reimbursement from the patient’s secondary and/or supplemental insurance if the patient has additional coverage, or our ability to collect amounts from individual patients.

Most patients are able to qualify for reimbursement and payment from Medicare, Medicaid, private insurance or combinations of the foregoing. We expect that subsequent generations of HFCWO products also will qualify for reimbursement under Medicare ~~Plan B~~ and most major health plans. However, some third-party payers must also approve coverage for new or innovative devices or therapies before they will reimburse health care providers who use the medical devices or therapies. In addition, we face the risk that new or modified products could have a lower reimbursement rate, or that the levels of reimbursement currently available for our existing products could decrease, which would hamper our ability to market and sell that product. Consequently, our sales will continue to depend in part on the availability of coverage and reimbursement from third-party payers, even though our devices may have been cleared for marketing by the FDA. The manner in which reimbursement is sought and obtained varies based upon the type of payer involved and the setting in which the procedure is furnished.

In response to the COVID-19 pandemic and the U.S. federal government’s declaration of a public health emergency in March 2020, CMS implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health emergency. These waivers are retroactively effective to March 1, 2020. Clinical indications and documentation typically required will not be enforced for respiratory related products including the SmartVest System (solely with respect to Medicare patients). The minimum documentation now requires a valid order and documentation of a respiratory-related diagnosis. Face-to-face and in-person requirements for respiratory devices are being waived ~~during such~~while the waiver is in place. The CMS waiver was recently extended in conjunction with the extension of the federal public health emergency for an additional 90-day period ~~which is currently scheduled to expire in October 2021.~~beginning July 15, 2022.

Our research and development (“R&D&D”) capabilities consist of full-time engineering staff and several consultants. We periodically engage consultants and contract engineering employees to supplement our development initiatives. Our team has a demonstrated record of developing new products that receive the appropriate product approvals and regulatory clearances around the world.

During fiscal ~~2021~~2022 and ~~2020,~~2021, we incurred R&D expenses of approximately $1,356,000 and $1,722,000, or 3.3% and ~~$1,050,000, or~~ 4.8% ~~and 3.2%~~ of our net revenues, respectively. As a percentage of sales, we expect spending on R&D expenses to decrease ~~slightly~~significantly during fiscal ~~2022~~2023 as compared with fiscal ~~2021,~~2022, as we conclude the design and testing of our next generation device in preparation for an anticipated product launch during the first half of fiscal ~~2023 product launch.~~2023. Product enhancements were driven by voice of customer survey and in-person information focused on patient useability and device portability. We also estimate that the next generation product will be a lower cost ~~bill~~ of ~~material~~goods compared to the SmartVest SQL.

As of June 30, ~~2021,~~2022, we held 1513 United States and ~~44 foreign issued~~43 foreign-issued patents covering the SmartVest System and its underlying technology and had 6413 pending United States and foreign patent applications. These patents and patent applications offer coverage in the field of air pressure pulse delivery to a human in support of airway clearance.

We generally pursue patent protection for patentable subject matter in our proprietary devices in foreign countries that we have identified as key markets for our products. These markets include the European Union, Japan, and other countries.

We also have received ~~ten~~10 U.S. and 100 foreign trademark and service mark ~~registrations, and one SmartVest registration in each of Canada, Peru, Japan, and India.~~registrations.

Our headquarters in New Prague, Minnesota includes a dedicated manufacturing and engineering facility of more than 14,000 square feet, and we are certified on an annual basis to be compliant with International Organization for Standardization (“ISO”) 13485 quality system standards. Our site has been audited regularly by the FDA and ISO, in accordance with their practices, and we maintain our operations in a manner consistent with their requirements for a medical device manufacturer. While components are outsourced to meet our detailed specifications, each SmartVest System is assembled, tested, and approved for final shipment at our manufacturing site in New Prague, consistent with FDA, Underwriters Laboratory, and ISO standards. Many of our strategic suppliers are located within 100 miles of our headquarters, which enables us to closely monitor our component supply chain. We maintain established inventory levels for critical components and finished goods to assure continuity of supply. During fiscal ~~2021~~2022 we experienced longer lead times for critical electronic components ~~certain plastic raw materials and packaging material~~ related to worldwide supply shortages due to COVID-19 and the related U.S. and global economic recovery. We did not experience any material disruptions to customer shipments in fiscal ~~2021.~~2022.

The original HFCWO technology was licensed to American Biosystems, Inc. (now part of Hill-Rom Holdings, Inc.) (“Hillrom”), which, until the introduction of our original MedPulse Respiratory Vest System^® in 2000, was the only manufacturer of a product with HFCWO technology cleared for market by the FDA (Hillrom’s The Vest^®Airway Clearance System). ~~Hillrom has also received FDA 510(k) clearance for the Monarch~~^®~~™ Airway Clearance System, a mobile device that uses pulmonary oscillating discs.~~ Respiratory Technologies, Inc. (now RespirTech, part of Koninklijke Phillips N.V.) received FDA clearance to market their HFCWO product, the inCourage^® Airway Clearance Therapy in 2005. Both Hillrom and RespirTech employ a direct-to-patient model, ~~and recently Royal Phillips announced plans to offer~~with RespirTech additionally offering its HFCWO device through selected ~~HME~~DME distributors.

The AffloVest^® from ~~International Biophysics Corporation~~Tactile Systems Technology Inc. (“~~IBC”~~Tactile Medical”) also participates in the same market as our SmartVest System. ~~IBC received FDA 510(k) clearance for its device in 2013. IBC~~Tactile Medical primarily sells its device through DME companies who distribute home care medical devices and supplies. Clinical and cost-effective evidence, technology innovations, including wireless connectivity, and HFCWO product features and benefits, such as size, weight of the generator, reputation for patient and reimbursement services, and sales effectiveness of field personnel, have become the key drivers of HFCWO product sales.

Based on annual revenue, we estimate that Hillrom maintains the highest market share in HFCWO followed by RespirTech with Electromed in the third ~~position followed by IBC.~~position.

Alternative products for administering pulmonary therapy include: Positive Expiratory ~~Pressure;~~Pressure, Intrapulmonary Percussive ~~Ventilation;~~Ventilation, CPT and breathing techniques. Physicians may prescribe some or all of these devices and techniques, depending upon each ~~patient’s~~patient's health status, severity of disease, compliance, or personal preference.

Key drivers of HFCWO product sales continue to be clinical and cost-effective evidence, technology innovations including wireless connectivity, and HFCWO patient experience benefits such as size, weight of the generator, and product reputation. We believe ~~our primary~~we distinguish ourselves in these areas with competitive advantages over alternative treatments ~~are~~ultimately improving the patient comfort, ease of use, and the effectiveness of HFCWO treatment. Because HFCWO is not “technique dependent,” as compared to most other alternative pulmonary therapy products, therapy ~~begins automatically once power is provided and~~ remains consistent and controlled for the duration of treatment.

Recent government and private sector initiatives in the U.S. and foreign countries aim at limiting the growth of health care costs ~~including~~including: price regulation, competitive pricing, coverage and payment policies, comparative effectiveness of therapies, technology assessments, and managed-care ~~arrangements, and~~arrangements. These initiatives are causing the marketplace to put increased emphasis on the delivery of more cost-effective medical devices that result in better clinical outcomes. Government programs, including Medicare and Medicaid, have attempted to control costs by limiting the amount of reimbursement the program will pay for particular procedures or treatments, restricting coverage for certain products or services, and implementing other mechanisms designed to constrain utilization and contain costs. Many private insurance programs look to Medicare as a guide in setting coverage policies and payment amounts. These initiatives have created an increasing level of price sensitivity among our customers.

Although we do not fall under competitive bidding for Medicare, we often must satisfy the same licensing requirements as other DME providers that qualify for competitive bidding. In response to out-of-state businesses winning the competitive bidding process, which had a significant impact on small local DME businesses, many states have enacted regulations that require a DME provider to have an in-state business presence, specifically through state HME licensing boards or through state Medicaid programs. In order to do business with any patients in the state or to be a provider for the state Medicaid program, a DME provider must have an in-state presence. In addition to Minnesota, the location of our corporate headquarters, we have a licensed in-state presence in three other states. We also maintain an in-state presence in California in order to meet their state Medicaid requirements. In-state presence requirements vary from state to state, but generally require a physical location that is staffed and open during regular business hours. We are licensed to do business in all states except for Alaska and Hawaii.

Our medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign regulatory agencies. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing, and distribution of our medical devices, and compliance with these laws and regulations entails significant costs for us. Our regulatory and quality assurance departments provide detailed oversight in their areas of responsibility to support required clearances and approvals to market our products.

In addition to the clearances and approvals discussed below, we obtained ISO 13485 certification in January 2005 and receive annual certification of our compliance to the current ISO quality standards.

We have received clearance from the FDA to market our products, including the SmartVest System. We may be required to obtain additional FDA clearance before marketing a new or modified product in the U.S., either through the 510(k) clearance process or the more complex premarket approval process. The process may be time consuming and expensive, particularly if human clinical trials are required. Failure to obtain such clearances or approvals could adversely affect our ability to grow our business.

In addition to its approval processes for new products, the FDA may require testing and post-market surveillance programs to monitor the safety and effectiveness of previously cleared products that have been commercialized and may prevent or limit further marketing of products based on the results of post-mark surveillance results. At any time after marketing clearance of a product, the FDA may conduct periodic inspections to determine compliance with both the FDA’s Quality System Regulation (“QSR”) requirements and current medical device reporting regulations. Product approvals by the FDA can be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial market clearance. The failure to comply with regulatory standards or the discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances, seizures or recalls of products (with the attendant expenses), the banning of a particular device, an order to replace or refund the cost of any device previously manufactured or distributed, operating restrictions and criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims.

We must register annually with the FDA as a device manufacturer and, as a result, are subject to periodic FDA inspection for compliance with the FDA’s QSR requirements that require us to adhere to certain extensive regulations. In addition, the federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. We also must maintain certain certifications to sell products internationally, and we undergo periodic inspections by notified bodies to obtain and maintain these certifications.

Advertising and marketing of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under health care reimbursement laws and consumer protection statutes. Competitors and others also can initiate litigation relating to advertising and/or marketing claims. If the FDA were to determine our promotional or training materials constitute promotion of an unapproved or uncleared claim of use, it is possible we would need to modify our training or promotional materials or be subject to regulatory or enforcement actions that could result in civil fines or criminal penalties. Other federal, state or foreign enforcement authorities could also take similar action if they were to determine that our promotional or training materials constitute promotion of an unapproved use, which could result in significant fines or penalties.

European Union rules require that medical products receive the right to affix the CE ~~marking,~~mark, demonstrating adherence to quality standards and compliance with relevant European Union Medical Device Directives (“MDD”). Products that bear CE ~~marking~~mark can be imported to, sold or distributed within the European Union. We obtained clearance to use the CE ~~marking~~mark on our products in April 2005. Renewal of CE marking is required every five years, and our notified body performs an annual audit to ensure that we are in compliance with all applicable regulations. We have maintained our CE marking in good standing since originally receiving it and most recently renewed it in January 2020. The renewal of our MDD certificate will allow us to continue to CE mark and sell our SmartVest SQL device, with no substantial changes, in the European Union until the certificate expires in May 2024. We are currently working on finalizing updates to the quality system to achieve full compliance with Regulation (EU) 2017/745 (EU MDR) which came into effect in May 2021. We also require all of our distributors in the European Union and other regions to comply with their home country regulations in our distributor agreements.

The Federal Physician Payments Sunshine Act (Section 6002 of the PPACA) (the “Sunshine Act”) was adopted on February 1, 2013, to create transparency for the financial relationship between medical device companies and physicians and/or teaching ~~hospitals.~~hospitals (covered recipients). In January 2021, the Sunshine Act was expanded to cover payments made to these additional covered recipients, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives. The Sunshine Act requires all manufacturers of drugs and medical devices to annually report to CMS any payments or any other “transfers of value” made to ~~physicians and teaching hospitals,~~any covered recipients, including but not limited to consulting fees, grants, clinical research support, royalties, honoraria, meals, and ~~meals.~~value of long-term use (over 90 days) of evaluation equipment. This information is then posted on a public website so that consumers can learn how much was paid to their physician by drug and medical device companies. The Sunshine Act requires ongoing data collection and annual management and reporting by us and imposes civil penalties for manufacturers that fail to report timely, accurately, or completely to CMS.

Federal health care laws apply to the marketing of our products and when we or our customers submit claims for items or services that are reimbursed under Medicare, Medicaid or other ~~federally-funded~~federally funded health care programs. The principal applicable federal laws include:

There are often similar state false claims, anti-kickback, and anti-self-referral and insurance laws that apply to state-funded Medicaid and other health care programs and private third-party payers. In addition, the U.S. Foreign Corrupt Practices Act can be used to prosecute companies in the U.S. for arrangements with physicians, or other parties outside the U.S. if the physician or party is a government official of another country and the arrangement violates the law of that country. Enforcement of all of these regulations has become increasingly stringent, particularly due to more prevalent use of the whistleblower provisions under the False Claims Act, which allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations, we and our officers and employees could be subject to severe criminal and civil penalties and disbarment from participation as a supplier of product to beneficiaries covered by Medicare or Medicaid.

Federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of such information. The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (“HIPAA”) and the Health Information Technology for Economic and Clinical Health Act (“HITECH”) set forth privacy and security standards that govern the use and disclosure of protected electronic health information by “covered entities,” which include healthcare providers, health plans and healthcare clearinghouses. Because we provide our products directly to patients and bill third-party payers such as Medicare, Medicaid, and insurance companies, we are a “covered entity” and must comply with these standards. Failure to comply with HIPAA and HITECH or any state or foreign laws regarding personal data protection may result in significant fines or penalties and/or negative publicity. In addition to federal regulations issued under HIPAA and HITECH, some states have enacted privacy and security statutes or regulations that, in some cases, are more stringent than those issued under HIPAA and HITECH. In those cases, it may be necessary to modify our planned operations and procedures to comply with the more stringent state laws. If we fail to comply with applicable state laws and regulations, we could be subject to additional sanctions.

The HIPAA and HITECH health care fraud and false statement statutes also prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private payers, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for health care benefits, items or services.

We are subject to various environmental laws and regulations both within and outside the U.S. Like other medical device companies, our operations involve the use of substances regulated under environmental laws, primarily manufacturing, sterilization, and disposal processes. We do not expect that compliance with environmental protection laws will have a material impact on our results of operations, financial position, or cash flows.

Protecting the privacy of customer and personnel information is important to us, and we maintain security protocols and processes, including ongoing training and education for all personnel, designed to combat the risk of unauthorized access or inadvertent disclosure. Our business operations involve confidential information, including patient health information subject to regulation as discussed under “HIPAA, HITECH and Other Privacy Regulations” above. Our information technology infrastructure is designed to offer reliability, scalability, performance, security and privacy for our personnel, clients and third-party contractors.

We maintain comprehensive compliance and security programs designed to help safeguard and ensure the integrity of the confidential information we possess, which includes both organizational and technical control measures. We also have programs in place to monitor the safety of confidential information as well as plans for immediate, coordinated action in the event of a potential security incident. We routinely conduct employee trainings on important information security procedures and engage with independent third-party firms to test and measure compliance on these security measures. In addition, we have maintained appropriate cyber insurance policies that limit the financial risk of any potential incident. Our cyber insurance policies include dedicated support for remediating a specific cybersecurity or data privacy incident and limit the potential financial risk associated with an actual incident.

Even though we have implemented administrative, physical and technical safeguards designed to help protect the confidential data we possess and the integrity of our information systems and infrastructure, these safeguards may not be effective in preventing future cybersecurity incidents or data breaches.

In June 2021, we determined that an unauthorized third party gained access to a limited number of our files. Upon discovery, we immediately initiated an investigation and engaged third-party advisors to assist in investigating the source and scope of the unauthorized activity, and to further secure our information systems. From the investigation, we determined that certain files containing certain information of customers, employees, and some third-party contractors were accessed. There has been no indication that any of this information has been used inappropriately and we are working to mitigate any impact on the Company. Individuals whose information may have been involved in the data privacy incident were specifically contacted by the Company. The Company has a cyber insurance policy which we believe will cover most of the costs associated with this specific data incident. To help prevent a similar incident from occurring in the future, we further enhanced the security of our systems, and will continue to review and, where appropriate enhance, our security protocols and processes, and training and education.

We believe that our dedicated, talented employees are our most valuable resource and a key strength in accomplishing our collective mission and goals. As of June 30, ~~2021,~~2022, we had ~~132~~156 employees, an increase of ~~8.2%~~15.4% from fiscal ~~2020,~~2021, who are located in 2429 states throughout the United States. 1018 of our employees were respiratory therapists licensed by appropriate state professional ~~organizations, including all the employees in our Patient Services Department.~~organizations. We also had approximately 250 respiratory therapists and health care professionals retained on a non-exclusive, independent contractor basis to provide training to our customers in the U.S. None of our employees are covered by a collective bargaining agreement. We believe our relations with our employees are good.

We are committed to attracting, retaining, and developing diverse and high-performing talent that includes a strong focus on performance and development, total rewards, diversity, inclusion and equity, and employee safety. These serve as the pillars to our human capital management framework.

We understand that our success and growth ~~depends~~depend on attracting, retaining, and developing talent across all levels of the organization. Our recruitment strategies are continuously reviewed with leadership and partners to ensure our practices align with our mission, purpose, and values.

We believe in ensuring that employees understand our mission, purpose, and goals as well as their impact on our success. We use an annual performance review process to support development and performance discussions with employees. In addition, every employee is eligible to participate in our incentive plan, which allows for us to share the rewards of the company with the people who significantly contribute to our success.

To cultivate a learning culture that provides enhancement and growth for our people, we offer educational assistance, online training (220 courses completed during fiscal 2022), seminars, specific skill training, and participation in business and industry organizations. We are also committed to contributing our talents and resources to serve the communities in which we live and work through various charitable campaigns, employee programs and volunteerism. We believe that this commitment assists in our efforts to attract and retain employees.

We believe that sharing rewards is essential to increasing employee engagement and improving morale and creating a positive culture. We also offer our employees a competitive salary and benefits package and are committed to continuous review of these programs. These benefits include but are not limited to retirement savings, a variety of health insurance options and other benefits programs, including dental and vision, disability insurance, contributions to health savings accounts, paid maternity/paternity leave, and wellness resources. In addition, we offer opportunities for remote work and flexible schedules and location, depending on business needs and the specific role.

We are committed to ensuring a diverse workforce in a safe environment by maintaining compliance with applicable employment laws and governmental regulations. Treating employees with dignity and equality is of utmost importance in everything we do. We take pride in the fact that women represent ~~52%~~53% of our total managerial roles and comprise ~~37.5%~~57% of our executive leadership team. We pride ourselves on accepting, hearing, and celebrating multiple approaches and points of view and building on an inclusive and diverse culture.

Safety is a vital aspect to the success of our people and business. We are proud of our employees’ collective commitment to secure and maintain safe work practices that have resulted in zero lost time injuries within our manufacturing operations. We also provide wellbeing services to support each employee’s physical and mental health and will continue to emphasize the importance of the safety and health of our employees in all we do.

Our Internet address is www.smartvest.com. We have made available on our website, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports, as soon as reasonably practicable after we electronically file these materials with, or furnish them to, the SEC. Reports of beneficial ownership filed by our directors and executive officers pursuant to Section 16(a) of the Exchange Act are also available on our website. We are not including the information contained on our website as part of, or incorporating it by reference into, this Annual Report on Form 10-K. The SEC also maintains an Internet site that contains our reports, proxy and information statements, and other information we file or furnish with the SEC, available at www.sec.gov.

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

We own our principal headquarters and manufacturing facilities, consisting of approximately 37,000 square feet, which are located on an approximately 2.3-acre parcel in New Prague, Minnesota. All of the Company’s revenues, profits, and assets are associated with this facility. We believe that our facilities are satisfactory for our long-term growth plans.

The disclosure regarding legal proceedings set forth in Note 11 to our Financial Statements in Part II, Item ~~3. Legal Proceedings.~~

We8 of this Annual Report on Form 10-K is incorporated herein by reference. Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of ~~business.~~business, including claims based on the assertions of patent and trademark infringement. Corresponding costs are accrued when it is probable that loss will be incurred, and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on our financial condition or results of operations.

~~Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.~~

As of August ~~20, 2021,~~23, 2022, there were 6559 registered holders of our common stock.

We have never paid cash dividends on any of our shares of common stock. We currently intend to retain any earnings for use in operations and do not anticipate paying cash dividends to our shareholders in the foreseeable future. The agreement governing our credit facility restricts our ability to pay dividends.

On May 26, 2021, our Board of Directors approved a stock repurchase authorization. Under the authorization, we ~~may~~were originally able to repurchase up to $3.0 million of outstanding shares of our common stock through May 26, 2022. On May 26, 2022, our Board of Directors removed the date limitation. The shares of our common stock may be repurchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. The following table sets forth information concerning purchases of shares of our common stock for the three months ended June 30, ~~2021:~~2022:

~~As a smaller reporting company, we are not required to provide disclosure pursuant to this item.~~

~~Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K. The forward-looking statements include statements that reflect management’s good faith beliefs, plans, objectives, goals, expectations, anticipations and intentions with respect to our future development plans, capital resources and requirements, results of operations, and future business performance. Our actual results could differ materially from those anticipated in the forward-looking statements included in this discussion as a result of certain factors, including, but not limited to, those discussed in the section entitled “Information Regarding Forward-Looking Statements” immediately preceding Part I of this Annual Report on Form 10-K.

Electromed develops and provides innovative airway clearance products applying HFCWO technologies in pulmonary care for patients of all ages.

We manufacture, market and sell products that provide HFCWO, including the SmartVest System that includes our newest generation SmartVest SQL® and previous generation SV2100 and related products, to patients with compromised pulmonary function. The SmartVest SQL is smaller, quieter and lighter than our previous product ~~(the SmartVest SV2100),~~ with enhanced programmability, ease of ~~use, wireless technology, and a personalized HFCWO therapy management portal for patients with compromised pulmonary function.~~use. Our products are sold in both the home health care market and the institutional market for use by patients in hospitals, which we refer to as “institutional sales.” The SmartVest SQL has been sold in the domestic home care market since 2014. In ~~2017,~~2015, we launched the SmartVest SQL into institutional and certain international markets. In June 2017, we announced the launch of the SmartVest SQL with SmartVest Connect™ wireless technology, which allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. SmartVest Connect ~~wireless technology.~~is currently available to pediatric and cystic fibrosis patients and was made available to certain targeted adult pulmonary clinics starting in November 2017. Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, bronchiectasis and repeated episodes of pneumonia. Additionally, we offer our products to a patient population that includes neuromuscular disorders such as cerebral palsy, muscular dystrophies, ALS, the combination of emphysema and chronic bronchitis commonly known as COPD, and patients with post-surgical complications or who are ventilator dependent or have other conditions involving excess secretion and impaired mucus transport.

The SmartVest System is often eligible for reimbursement from major private insurance providers, health maintenance organizations (“HMOs”), state Medicaid systems, and the federal Medicare system, which we believe is an important consideration for patients considering an HFCWO course of therapy. For domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code (E0483) for HFCWO devices if the patient has cystic fibrosis, bronchiectasis (including chronic bronchitis or ~~chronic obstructive pulmonary disease~~COPD that has resulted in a diagnosis of bronchiectasis), or any one of certain enumerated neuromuscular diseases, and can demonstrate that another less expensive physical or mechanical treatment did not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting their coverage policies and payment amounts.

We employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients and their clinicians, deliver our solutions to patients and train them on proper use in their homes. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional durable medical equipment channel and capture both the manufacturer and distributor margins. We have engaged a limited number of regional durable medical equipment distributors focused on respiratory therapies as an alternate sales channel. Revenue through this channel was ~~less than 2%~~4% of our total revenues in fiscal ~~2021.~~2022.

~~Grow faster than the overall home care HFCWO market~~2023 are to: accelerate our revenue growth by taking market share and expanding the ~~pool of physicians who prescribe the SmartVest System in~~addressable population for the largest and fastest growing segments of the market: adult pulmonology/~~bronchiectasis;~~bronchiectasis. Actions to support accelerating our growth include the following:

During the preparation of our financial statements, we are required to make estimates, assumptions and ~~judgments~~judgment that affect reported amounts. Those estimates and assumptions affect our reported amounts of assets and liabilities, our disclosure of contingent assets and liabilities, and our reported revenues and expenses. We update these estimates, assumptions, and ~~judgments~~judgment as ~~appropriate, which in most cases is at least quarterly. We use our technical accounting knowledge, cumulative business experience, judgment and other factors in the selection and application~~appropriate. Some of our accounting ~~policies. While we believe~~policies and estimates require us to exercise significant judgment in selecting the ~~estimates,~~appropriate assumptions ~~and~~for calculating financial statements. Such judgments ~~we use in preparing our financial statements are appropriate, they~~ are subject to an inherent degree of uncertainty. Among other factors, these judgments are based upon our historical experience, known trends in our industry, terms of existing contracts and ~~uncertainties regarding their outcome and therefore, actual results may materially differ~~other information from ~~these estimates.~~outside sources, as appropriate. The following is a summary of our primary critical accounting policies and estimates. See also Note 1 to the Financial Statements, included in Part II, Item 8, of this Annual Report on Form 10-K.

Impacts of COVID-19 ~~Pandemic~~on Our Business and ~~CARES Act Funding~~Operations

In March 2020, the World Health Organization designated COVID-19 as a global pandemic. The COVID-19 pandemic created significant volatility, uncertainty and economic disruption that negatively impacted business in our industry starting in March 2020 and continuing to varying degrees throughout fiscal 2021.

We consider our business to be essential under applicable governmental orders due primarily to our role in manufacturing and supplying needed medical devices to patients with respiratory related issues and remained fully operational for the duration of fiscal 2021.

We also took measures to ensure the safety of our employees and to comply with applicable governmental orders, including transitioning employees to remote work where possible, adhering to Centers for Disease Control (“CDC”) guidelines for mask wearing and social distancing, and implementing enhanced cleaning practices in the office. During the fourth quarter of fiscal 2021, as COVID-19 vaccines became more widely available in the United States, we reviewed our guidelines for corporate offices and manufacturing and adjusted our safety guidelines to align with CDC guidelines for mask wearing and social distancing. Additionally, we provided direction to employees on their work schedules, balancing business productivity and flexibility for employees and maintaining the highest level of safety in the workplace.

The home care market was impacted by COVID-19 primarily due to certain healthcare facilities and clinics restricting access to their clinicians, and patients reducing in-person visits to clinics for consultations and treatments. The degree of clinic access limitations and in-person patient visit reductions varied throughout fiscal 2021 based on multiple variables, including the number of daily COVID-19 cases occurring in key geographies, the degree of state and local government restrictions, and the availability and deployment of vaccines. During fiscal 2021, our sales team developed and utilized a hybrid selling approach that combined virtual and face-to-face clinician interactions, which helped mitigate the market disruption caused by COVID-19.

Our institutional business was negatively impacted by COVID-19 through fiscal 2021 as hospitals and long-term care facilities adjusted their operating protocols and procurement management in response to the pandemic. Limiting the spread of airborne particles was a priority in institutional settings during fiscal 2021, and airway clearance therapies usage, including HFCWO, induces coughing in patients.

In response to the negative impacts of the COVID-19 pandemic on our business, in April 2020 we initiated cost-containment measures, which included reducing discretionary and variable spend, such as travel, and the use of contractors, consultants, temporary help and employee furloughs in our manufacturing and general and administrative functions due to lower near-term demand for our products. As our referral volumes returned to near pre-pandemic levels in July 2020, all furloughed employees returned to work by August 2020, and we continued to make all planned strategic investments in our business throughout fiscal 2021 in both selling, general and administrative (“SG&A”) and R&D.

We did not receive any direct financial assistance from any government program during fiscal 2021. We received a one-time $913,000 payment under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) in the fourth quarter of fiscal 2020, which partially offset lower profitability related to the revenue decline caused by the COVID-19 pandemic during the period. The amount received from the CARES Act is subject to compliance with certain terms and conditions and reporting requirements, and such report may be audited by a federal agency for compliance with the program’s terms and conditions.

Overall, we believe that these and other responses by healthcare systems had a negative impact on our operating results and cash flows during the fourth quarter of fiscal 2020 and the first quarter of fiscal 2021, and then again in the third quarter of fiscal 2021 as Covid-19 cases and hospitalization spiked during that time period. We believe that we benefited during the most recent fiscal year from our sales organization adapting to innovations in contacting physicians, such as through virtual meetings, and from the waiver implemented by CMS in response to the public health emergency.

~~In response to the COVID-19~~ pandemic, and the U.S. ~~federal government’s declaration~~Department of Health and Human Services designated COVID-19 as a public health ~~emergency, CMS implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health~~ emergency. These waivers were made retroactively effective to March 1, 2020 and were in place for the duration of fiscal 2021. Clinical indications and documentation typically required were not enforced for respiratory related products including the SmartVest System (solely with respect to direct Medicare covered patients) applicable for our home care prescriptions. The minimum documentation now requires a valid order and documentation of a respiratory related diagnosis. Face-to-face and in-person requirements for replacement respiratory devices are being waived during such period, both of which are currently scheduled to expire in October 2021. A temporary suspension of a 2% tax on Medicare payments was also initiated in May 2020 and has been extended through December 2021.

The impact of the COVID-19 pandemic on our business remains uncertain, and its effects on our operational and financial performance will depend in part on future developments, which cannot be reasonably estimated at this time. Such future developments include, but are not limited to, the duration, scope and severity of the COVID-19 pandemic in geographic areas in which we operate or in which our patients live, actions taken to contain or mitigate its impact, the impact on governmental healthcare programs and budgets, the ~~deployment~~development and distribution of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and evolving situation, we are unable to predict with confidence the likely impact of the COVID-19 pandemic on our future operations.

During fiscal 2022, we experienced a reduction in the number of clinics allowing face-to-face access by our sales team although not to the extent experienced in fiscal 2021 as the number of infections relating to the Omicron variant and related subvariants of COVID-19 increased throughout most regions of the United States, and hospitals implemented additional safety protocols. Our sales team continued to utilize a hybrid sales process of virtual and face-to-face clinician interaction with strict adherence to specific clinic and healthcare system safety protocols, which we believe allowed them to drive stronger referral growth compared to fiscal 2021. During the second half of fiscal 2022, we observed an improvement in clinic access and patient flow compared to earlier in the fiscal year, which we believe is likely a result of Omicron-related case reductions throughout most of the United States, contributing to a record high number of monthly referrals for our company.

We believe that the impact of the COVID-19 pandemic on our home care and institutional business will continue during at least the beginning of fiscal 2023. Our home care revenue for fiscal 2022 has increased as compared to fiscal 2021; however, if COVID-19 infection rates increase and federal, state and local restrictions on commerce, stay-at-home orders or other restrictions on businesses are reinstated, we believe that such measures could have a material adverse effect on our business.

We observed increased changes to our supply chain timelines and increased material and shipping costs during the second half of fiscal 2022, but we did not experience any disruptions that materially impacted product availability for our customers. We anticipate that increased material and shipping costs will continue during fiscal 2023 relating to supply chain availability and inflationary trends in electronic components but may extend to other components as well. In certain instances, we have purchased key electronic materials in advance to ensure adequate future supply and mitigate the risk of supply chain disruption. It is possible that the COVID-19 pandemic could have a greater adverse impact on our supply chain in the future, including impacts associated with preventative and precautionary measures taken by other businesses and applicable governments. A reduction or interruption in any of our manufacturing processes could have a material adverse effect on our business. Any significant increases to our raw material or shipping costs could reduce our gross margins.

We have also taken measures to ensure the safety of our employees and to comply with applicable governmental orders. We consider our business to be essential under applicable governmental orders, primarily due to our role in manufacturing and supplying needed medical devices to patients with respiratory-related issues and have therefore continued to operate during the government restrictions put in place in response to the pandemic.

In response to the COVID-19 pandemic and the U.S. federal government’s declaration of a public health emergency, the CMS implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health emergency. These waivers became effective on March 1, 2020. Clinical indications and documentation typically required will not be enforced for respiratory-related products including the SmartVest System (solely with respect to Medicare patients). The minimum documentation now requires a valid order and documentation of a respiratory-related diagnosis. Face-to-face and in-person requirements for respiratory devices are being waived while the waiver is in place. The CMS waiver was recently extended in conjunction with the extension of the federal public health emergency for an additional 90-day period beginning July 15, 2022.

We did not receive any direct financial assistance from any government program during fiscal 2021 or fiscal 2022 in connection with COVID-19 relief measures.

~~We measure revenue~~Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including ~~noncash consideration,~~ consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs,” or the requirements under other applicable accounting guidance are met.

The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of ~~each~~the Company’s SmartVest System after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues.

Accounts receivable are also net of an allowance for doubtful accounts, which are accounts from which payment is not expected to be received. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition and credit history. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.

We request that customers return previously sold units that are no longer in use to us in order to limit the possibility that such units would be resold by unauthorized parties or used by individuals without a prescription. The customer is under no obligation to return the product; however, we do reclaim the majority of previously sold units upon the discontinuance of patient usage. We are certified to recondition and resell returned SmartVest System units. Returned units are typically reconditioned and resold and continue to be used for demonstration equipment and warranty replacement parts.

Long-lived assets, primarily property and equipment and finite-life intangible assets, are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. In evaluating recoverability, the following factors, among others, are considered: a significant change in the circumstances used to determine the amortization period, an adverse change in legal factors or in the business climate, a transition to a new product or service strategy, a significant change in customer base, and a realization of failed marketing efforts. The recoverability of an asset or asset group is measured by a comparison of the unamortized balance of the asset or asset group to future undiscounted cash flows. If we believe the unamortized balance is unrecoverable, we would recognize an impairment charge necessary to reduce the unamortized balance to the estimated fair value of the asset group. The amount of such impairment would be charged to operations at the time of determination.

~~Property and equipment~~Inventories are stated at the lower of cost ~~less accumulated depreciation. We use~~(first-in, first-out method) or net realizable value. Work in process and finished goods are carried at standard cost, which approximates actual cost, and includes materials, labor and allocated overhead. The reserve for obsolescence is determined by analyzing the straight-line method for depreciating property and equipment over their estimated useful lives, which range from three to 39 years. Our finite-life intangibles consist of patents and trademarks and their carrying costs include the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively, using the straight-line method.

~~An allowance for potentially slow-moving or excess inventories is made based on our analysis of~~ inventory ~~levels~~ on hand and comparing it to expected future ~~production requirements, sales forecasts and current estimated market values.~~sales. Estimated inventory to be returned is based on how many devices that have shipped that are expected to be returned prior to completion of the insurance reimbursement process.

We provide a warranty on the SmartVest System that covers the cost of replacement parts and labor, or a new SmartVest System in the event we determine a full replacement is necessary. For each home care SmartVest System initially purchased and currently located in the U.S. or Canada, we provideThe Company provides a lifetime warranty on its products to the ~~individual~~prescribed patient for ~~whom the SmartVest System is prescribed. For~~ sales ~~to institutions~~ within the U.S., and a three-year warranty for all ~~international~~institutional sales ~~except Canadian home care, we provide a three-year warranty. We estimate, based upon a review of historical warranty claim experience,~~and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under ~~our~~its warranty ~~policies~~ and ~~record~~records a liability in the amount of such ~~estimate~~costs at the time athe product is sold. The warranty cost is based on future product performance and durability and is estimated largely based on historical experience. We estimate the average useful life of our products is approximately five years.shipped. Factors that affect ~~our~~the Company’s warranty ~~liability~~reserve include the number of units ~~sold,~~shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. ~~At our discretion, based upon the cost to either repair or replace a product, we have occasionally replaced such products covered under warranty with a new or refurbished model. We~~The Company periodically ~~assess~~assesses the adequacy of ~~our~~its recorded warranty ~~liability~~reserve and ~~adjust~~adjusts the ~~accrual~~amounts as ~~claims data and historical experience warrant.~~necessary.

Share-based payment awards consist of options to purchase shares of our common stock issued to employees. Expense for share-based payment awards consist of options to purchase shares of our common stock issued to employees for services. Expense for options is estimated using the Black-Scholes pricing model at the date of ~~grant. The portion of~~grant and expense for restricted stock is determined by the ~~option award that~~closing price on the day the grant is ~~ultimately expected to vest~~made. Expense is recognized on a straight-line basis over the requisite service or vesting period of the award, ~~and adjusted upon completion of~~or at the ~~vesting period.~~time services are provided for non-employee awards. In determining the fair value of ~~our share-based payment awards,~~options, we make various assumptions using the Black-Scholes pricing model, including expected risk-free interest rate, stock price volatility, ~~life~~ and ~~forfeitures.~~life. See Note 8 to the Financial Statements included in Part II, Item 8, of this Annual Report on Form 10-K for a description of these assumptions.

Fiscal Year Ended June 30, ~~2021~~2022 Compared to Fiscal Year Ended June 30, ~~2020~~2021

Revenue for the fiscal years ended June 30, ~~2021~~2022 and ~~2020~~2021 are summarized in the table below (dollar amounts in thousands).

	Fiscal Years Ended June 30,									Fiscal Years Ended June 30,
	2021		2020		Increase (Decrease)					2022		2021		Increase (Decrease)
Home Care Revenue	$	32,986,000	$	29,323,000	$	3,663,000		12.5	%	$	38,004,000	$	32,986,000	$	5,018,000		15.2	%
Institutional Revenue		1,549,000		2,000,000		(451,000	)	(22.6	%)		1,660,000		1,549,000		111,000		7.2	%
Home Care Distributor Revenue		563,000		430,000		133,000		30.9	%		1,474,000		563,000		911,000		161.8	%
International Revenue		658,000		718,000		(60,000	)	(8.4	%)		521,000		658,000		(137,000	)	(20.8	%)
Total Revenue	$	35,756,000	$	32,471,000	$	3,285,000		10.1	%	$	41,659,000	$	35,756,000	$	5,903,000		16.5	%

Home Care Revenue. Home care revenue increased by ~~12.5%~~$5,018,000, or 15.2%, ~~or approximately $3,663,000, for~~in fiscal ~~2021~~2022 compared to fiscal ~~2020..~~2021. The ~~growth versus prior year~~revenue increase compared to fiscal 2021 was primarily ~~driven by an increase~~due to increases in referrals and approvals. The increase in referrals ~~compared to the prior year periods~~ was primarily due to ~~the~~an increase in direct sales representatives, increased sales representative productivity driven by increased clinic access and patient flow, our sales team ~~adapting to a hybrid virtual~~refining their selling process and ~~face-to-face selling model implemented to combat~~ clinic ~~access limitations due to the COVID-19 pandemic,~~targeting methodology, and benefits of the CMS waiver on the non-commercial Medicare portion of our home care ~~revenue, and an~~revenue. Additionally, we also benefitted from a Medicare allowable rate increase that took effect on January 1, 2022. Annual Medicare rate increases for our device are linked closely to changes in ~~direct sales representatives.~~the Urban Consumer Price Index.

The CMS waiver benefited the non-commercial Medicare portion of our home care revenue by increasing the number of referrals and the approval percentage for previously non-covered diagnoses. We believe that our ongoing sales team execution, along with the expected return to pre-COVID-19 levels of patient face-to-face engagement with physicians and clinic access for our sales team, has the potential to mitigate the impact of a CMS waiver expiration, which is currently effective until October ~~2021.~~2022.

Institutional Revenue. Institutional revenue ~~decreased~~increased by ~~22.6%,~~$111,000, or ~~approximately $451,000,~~7.2%, in fiscal ~~2021~~2022 compared to fiscal ~~2020.~~2021. Institutional revenue includes sales to group purchasing organizations, rental companies and other institutions. The ~~decrease in the current year periods~~revenue increase was ~~primarily~~ due to ~~the continued impact of COVID-19 on hospital purchasing activity. Our institutional revenue~~ increased ~~each quarter throughout~~capital purchases and stronger consumable volumes compared to fiscal 2021, as ~~hospital purchasing activity began returning to more standard operating procedures as were~~hospitals resumed utilization of HFCWO protocols after reducing utilization early in ~~place prior to COVID-19.~~the COVID-19 pandemic.

Home Care Distributor Revenue. Home care distributor revenue increased ~~30.9%~~by $911,000, or 161.8%, ~~or approximately $133,000, for~~in fiscal ~~2021~~2022 compared to fiscal ~~2020.~~2021. The ~~growth versus the prior year~~revenue increase in fiscal 2022 was ~~driven by additional capital sales with~~due to increased demand from one of our primary ~~distributor.~~home care distribution partners. We began selling to a limited number of home medical equipment distributors during our fiscal year ended June 30, 2020, who in turn sell our SmartVest System in the U.S. home care market.

International Revenue. International revenue decreased by ~~8.4%,~~$137,000, or ~~approximately $60,000,~~20.8%, in fiscal ~~2021~~2022 compared to fiscal ~~2020.~~2021. International revenue growth is not currently a primary focus for us, and our corporate resources are ~~only~~ focused on supporting and maintaining our current distributors. International sales are affected by the timing of international distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis.

Gross profit increased to ~~$27,305,000 during~~$31,442,000 in fiscal ~~2021,~~2022, or 75.5% of net revenues, from $27,305,000, or 76.4% of net revenues, ~~from $25,200,000, or 77.6% of net revenues, during~~in fiscal ~~2020.~~2021. The increase in gross profit was primarily related to increases in domestic home care ~~revenue.~~revenue including the Medicare allowable rate increase that took effect in January 2022. The decrease in gross profit as a percentage of net revenue was driven by a higher ~~warranty reserve adjustment, costs associated with discontinuing shipments of the SmartVest SV2100 in the United States, and limited cost increases to both~~ raw ~~materials~~material and shipping costs ~~which was partially offset by a higher mix of home care revenue and a favorable mix of Medicare within the home care channel. The~~as well as patient training related expenses due to increase in the warranty reserve was driven by a combination of an increase in components included in the warranty calculation and higher repair costs for our SV2100 device repairs. There has not been an increase in product warranty returns for either our generators or vests.face-to-face trainings.

We believe as we continue to grow revenue, we will be able to leverage manufacturing costs, although there may be fluctuations on a short-term basis related to increased material and shipping costs as well as average reimbursement based on the mix of referrals during any given period. Factors such as diagnoses that are not assured of reimbursement, insurance programs with lower allowable reimbursement amounts (for example, state Medicaid programs), ~~and~~ whether an individual patient meets prerequisite medical criteria for reimbursement, and continuation of the Medicare waiver currently in place may have an effect on average reimbursement received on a short-term ~~basis~~basis. We have a goal of improving our gross margin percentage over time due to lower product costs associated with our next generation product, supplier optimization, and gaining operating leverage on higher volumes.

Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A&A”) expenses ~~increased by approximately $2,498,000, or 12.5%, to approximately $22,443,00~~were $27,114,000 in fiscal ~~2021, compared to approximately $19,945,000~~2022, representing an increase of $4,671,000 or 20.8% from $22,443,000 in fiscal 2020. During fiscal 2021, we invested in strategic SG&A investments that we believe will position the company for sustainable, long-term growth. Key strategic SG&A investments in fiscal 2021 included increased direct-to-consumer marketing, implementation of a new revenue cycle management system, strategic market analytics and commercial planning and new headcount positions in product marketing and clinical field support. We believe that these investments will provide the support to drive a successful sales force expansion plan beginning in fiscal 2022.2021.

SG&A payroll and compensation-related expenses increased by ~~$1,973,000,~~$2,206,000, or ~~15.8%~~15.3%, to $16,640,000 in fiscal 2022, compared to $14,434,000 in fiscal ~~2021, compared to $12,461,000~~2021. The increase in ~~fiscal 2020. The increase~~the current year was primarily due to a higher average number of sales, sales support and marketing personnel, increased reimbursement personnel to process higher patient referrals, increased temporary resources to assist with systems infrastructure investments and increased ~~compensation~~incentive payments ~~related to stronger~~on higher home care ~~revenue performance.~~revenue. We have also continued to provide regular merit-based increases for our employees and are regularly benchmarking our compensation ranges for new and existing employees to ensure we can hire and retain the talent needed to drive growth in our business. Field sales employees totaled 52, of which 43 were direct sales, as of June 30, 2022, compared to 46 as of June 30, 2021, of which 37 were direct sales.

Professional and legal fees increased by ~~$431,000,~~$875,000, or ~~21.5%~~36.0%, to $3,308,000 in fiscal 2022, compared to $2,433,000 in fiscal ~~2021, compared to $2,002,000 in fiscal 2020. These~~2021. Professional fees ~~are primarily for~~include services related to legal costs, shareowner services and reporting requirements, information technology technical support and consulting ~~fees for enhancing our market development strategy.~~fees. The increase in the current year ~~periods~~ was primarily due to ~~higher legal fees, annual fees associated with~~ a ~~new human resources platform,~~shareholder activism matter, increased investment in ~~leadership development training,~~our system infrastructure and ~~fees associated~~increased clinical study costs. Our shareholder activism matter concluded with ~~the implementation~~a cooperation agreement in September 2021. We continue to make key investments in systems infrastructure including implementing a new enterprise resource planning (“ERP”) system, enhancing our customer relationship management system and further optimizing of ~~our new~~the revenue cycle management ~~software.~~system that was implemented in June 2021. We expect these system infrastructure investments will result in more efficient and scalable operational processes and provide enhanced analytics to ~~make continued investments~~drive business performance. We also expect to continue investing in our ~~systems infrastructure over~~on-going clinical studies in order to continue building the ~~next year, including an enterprise resource planning software implementation.~~body of evidence around positive outcomes from bronchiectasis patients using HFCWO and SmartVest therapy.

Total discretionary marketing expenses ~~increased~~decreased by ~~$281,000,~~$238,000, or ~~36.0%~~22.4% to ~~$1,062,,000~~$824,000 in fiscal ~~2021,~~2022, compared to ~~$781,000~~$1,062,000 in fiscal ~~2020.~~2021. The decrease in the current year was primarily due to a shift to more cost-effective direct-to-consumer marketing investments.

Travel, meals and entertainment expenses increased $734,000, or 41.2%, to $2,514,000 for fiscal 2022 compared to $1,780,000 in fiscal 2021. The increase in the current year period was primarily due to ~~a direct-to-consumer marketing campaign~~our sales team resuming closer-to-normal levels of travel compared to the COVID-19 driven travel restrictions in the prior year and an increase in regional sales meetings that ~~began~~were cancelled in ~~May 2020~~the prior year due to COVID-19. The Company also held an in-person national sales meeting in August 2021 whereas the national sales meeting was held virtually in fiscal 2021 due to COVID-19.

Recruiting fees increased by $362,000 or 134.6% to $631,000 for fiscal 2022 compared to $269,000 in fiscal 2021. The increase in recruiting fees is primarily due to increased recruiting for senior leadership and ~~investment~~direct sales representative positions.

Insurance expenses increased by $229,000 or 20.6% to $1,339,000 for fiscal 2022 compared to $1,110,000 in ~~strategic market analytics~~fiscal 2021. The increase in the current year is primarily due to higher health insurance, director and ~~commercial planning activities.~~officer insurance costs and cyber insurance costs.

R&D expenses decreased ~~$164,000,~~by $366,000, or ~~8.4%~~21.3%, to ~~$1,780,000 for~~$1,356,000 in fiscal ~~2021~~2022 compared to ~~$1,944,000~~$1,722,000 in fiscal ~~2020.~~2021. The decrease in the current year ~~period~~ was primarily due to travel reductions in connection with COVID-19, primarily in the first half of the fiscal year. Travel, meals and entertainment expenses returned to near pre-COVID-19 levels by the fourth quarter of fiscal 2021.

~~Research and Development Expenses.~~ R&D expenses increased by $672,000, or 64.0%, to $1,722,000 in fiscal 2021 compared to $1,050,000 in fiscal 2020. R&D expenses were 4.8% of revenue in fiscal 2021 compared to 3.2% of revenue in fiscal 2020. The increase in the current year period was primarily due toreduced professional consulting ~~fees~~costs associated with our next generation platform development activities. R&D expenses were 3.3% of revenue in fiscal 2022 compared to 4.8% of revenue in fiscal 2021. We expect R&D spending to ~~remain~~be between ~~3.0%~~2.0% and ~~5.0%~~3.0% of revenue during fiscal ~~2022,~~2023, as we look to finalize our development and product testing work in preparation for an anticipated fiscal year 2023 next generation product launch.

~~Government Stimulus Income.~~ We did not record any government stimulus income in fiscal 2021. In fiscal 2020, we recorded $913,000 of government stimulus income related to general distribution funds received from the Provider Relief Fund established by the CARES Act for Medicare fee-for-service providers due to lost revenues resulting from the COVID-19 pandemic.

Net interest income was approximately ~~$39,000 during~~$25,000 in fiscal ~~2021~~2022 compared to net interest income of ~~$121,000~~$39,000 in fiscal ~~2020.~~2021. The decrease in ~~net interest income~~the current year was primarily ~~driven by~~due to lower ~~interest~~ rates earned on our cash deposits and lower cash deposits in ~~fiscal 2021 as~~the bank compared to prior fiscal ~~2020.~~periods.

Net other expense was approximately $12,000 during fiscal 2021 compared to net other expense of zero in fiscal 2020. Net other expenses represent costs related to our June 2021 data security incident of $187,000, net of related insurance reimbursement of $175,000.

Income tax expense in fiscal 2022 was 692,000, which includes a current tax expense of $1,181,000 and a deferred benefit of $489,000. Estimated income tax expenses include a discrete current tax benefit of approximately $37,000 related to exercised fully vested stock options and a discrete current benefit of approximately $21,000 related to the excess tax benefit of non-qualified stock options that were exercised during the period.

Income tax expense in fiscal 2021 was $805,000, which ~~includes~~included a current tax expense of $1,099,000 and a deferred benefit of $294,000. Estimated income tax expense ~~includes~~included a discrete deferred tax expense of approximately $81,000 related to unexercised fully vested stock options that expired and a discrete current tax benefit of approximately $33,000 related to the excess tax benefit of non-qualified stock options that were exercised during the period.

In fiscal 2020, we recorded a current income tax expense of $1,078,000, which includes a current tax expense of $1,204,000 and a deferred benefit of $126,000. Estimated income tax expense for fiscal 2021 included a discrete current tax benefit of approximately $358,000 related to the excess tax benefit of non-qualified stock options that were exercised during the period.

The effective tax rates were ~~25.4%~~23.1% and ~~20.6%~~25.4% for fiscal ~~2021~~2022 and ~~2020,~~2021, respectively. The effective tax rates differ from the statutory federal rate due to the effect of state income taxes, R&D tax credits, and other permanent items that are non-deductible for tax purposes relative to the amount of taxable income.

Net income for fiscal ~~2021~~2022 was ~~$2,362,000,~~$2,305,000, compared to net income of ~~$4,161,000~~$2,362,000 in fiscal ~~2020.~~2021. The decrease in ~~the~~ current year ~~period~~net income was ~~driven by~~primarily due to increased strategic investments in SG&A, shareholder activism costs and ~~R&D and a lower gross margin percentage,~~higher product costs partially offset by stronger home care and distributor revenue ~~performance. Fiscal year 2021 does not include any government stimulus income, compared to $913,000 of government income received under the CARES Act in fiscal 2020.~~ growth.

Net cash ~~provided by~~used in operating activities in fiscal ~~2021~~2022 was ~~$3,077,000.~~$686,000. Cash flows from operating activities consisted of net income of ~~$2,362,000,~~$2,305,000, non-cash expenses of approximately ~~$1,340,000,~~$1,115,000, a ~~$1,284,000~~$2,170,000 increase in accounts payable and accrued liabilities ~~a decrease in inventory of $971,000,~~and a decrease in contract assets of ~~$510,000 and a $151,000 decrease in prepaid expenses.~~$107,000. These cash flows from operating activities were ~~partially~~ offset by a ~~$4,091,000~~$4,020,000 increase in accounts ~~receivable.~~receivable, an increase in inventory of $1,072,000, and a $1,322,000 increase in prepaid expenses. The increase in accounts receivable was primarily due to an increase in the Medicare portion of our home care business, which has a 13-month payment cycle. Three distinct items have negatively impacted our operating cash flow in fiscal 2022, including tax payments on higher-than-expected fiscal 2021 net income, increased payments to secure adequate supply of key raw material components, and a one-time payout of accrued vacation balances as part of an enhancement to our paid time off policy. Our cash receipt collection remains strong, with the three months ended June 30, 2022 period having the highest cash receipt collections in our company's history, building upon the prior record that was set in the previous quarter.

Net cash used in investing activities in fiscal ~~2021~~2022 was approximately ~~$448,000.~~$1,525,000. Cash used in investing activities consisted of approximately ~~$287,000~~$1,425,000 in expenditures for property and equipment, approximately $943,000 for software and ~~$161,000~~$482,000 for equipment, and $100,000 in payments for patent and trademark costs.

Net cash used in financing activities in fiscal ~~2021~~2022 was approximately ~~$1,219,000,~~$1,525,000, consisting of ~~$1,124,000~~$1,448,000 used for our share repurchase program and ~~$141,000~~$77,000 for taxes paid on ~~behalf~~net share settlements of ~~employees~~ stock ~~options that were exercised on a net basis during the period, partially offset by $46,000 of proceeds received from stock options exercised during the period.~~option exercises.

Our primary working capital requirements relate to adding employees to our sales force and support functions, continuing ~~R&D efforts,~~infrastructure investments, and supporting general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course of business. Based on our current operational performance, we believe our working capital of approximately ~~$27,065,000~~$27,389,000 and available borrowings under our existing credit facility will provide adequate liquidity for fiscal ~~2022.~~2023.

Effective December ~~16, 2020,~~17, 2021, we renewed our credit facility, which provides us with a revolving line of credit. Interest on borrowings on the line of credit accrues at the prime rate ~~(3.25%~~(4.75% as of June 30, ~~2021)~~2022) less ~~1.00%~~1.0% and is payable monthly. There was no outstanding principal balance on the line of credit as of June 30, ~~2021~~2022 or June 30, ~~2020.~~2021. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or ~~57.00%~~57.0% of eligible accounts receivable, and the line of credit expires on December 18, ~~2021,~~2023, if not renewed. As of June 30, ~~2021,~~2022, the maximum $2,500,000 was available under the line of credit. Payment obligations under the line of credit are secured by a security interest in substantially all of our tangible and intangible assets.

The documents governing our line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than $10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends.

Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of our indebtedness, preventing access to additional funds under the line of credit, requiring prepayment of outstanding indebtedness, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue operations as planned. If we are unable to repay such indebtedness, the lender could foreclose on these assets.

During fiscal ~~2021~~2022 and ~~2020,~~2021, we spent approximately ~~$299,000~~$1,425,000 and ~~$844,000,~~$287,000, respectively, on property and equipment. We currently expect to finance planned equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flows.

~~Off-Balance Sheet Arrangements~~While the impact of the COVID-19 pandemic and other factors such as inflation are difficult to predict, we believe our cash, cash equivalents and cash flows from operations will be sufficient to meet our working capital, capital expenditure, operational cash requirements for fiscal 2023.

~~In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update No. 2019-12,~~ ~~Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.~~ The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. generally accepted accounting principles for other areas of Topic 740 by clarifying and amending the existing guidance. The guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effectSee Note 1 of the Notes to our Financial Statements in this Annual Report on Form 10-K for information on new ~~guidance.~~accounting standards adopted in fiscal 2022 or pending adoption.

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

We have audited the accompanying balance sheets of Electromed, Inc. (the Company) as of June 30, ~~2021~~2022 and ~~2020,~~2021, the related statements of operations, shareholders’ equity and cash flows for the years then ended, and the related notes to the financial statements. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, ~~2021~~2022 and ~~2020,~~2021, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

As discussed in Note 2 to the financial statements, revenues are recognized at a point in time when control passes to the customer upon product shipment or delivery. Net patient revenues (patient revenue less estimated adjustments) are recognized at the estimated net realizable amounts from third-party ~~payors~~payers and customers in exchange for the product. The Company has agreements with third-party ~~payors~~payers that provide for payments at amounts different from its established rates. Each quarter, the Company estimates its adjustments for each sale based on the terms of third-party ~~payor~~payer contracts and ~~the~~ historical ~~collection and write-off~~collections experience, ~~and~~then applies an estimate for an adjustment reserve percentage to the gross accounts receivable balances.

We identified the measurement of the adjustment reserve related to customer revenue ~~net of adjustments~~ as a critical audit matter due to the audit effort, degree of auditor judgment, and subjectivity involved in evaluating the audit evidence related to ~~the adjustment reserves.~~management's estimate.

Our audit procedures related to the ~~Company’s~~Company's measurement of ~~customer revenue net of adjustments~~the adjustment reserve included the following, among others.


	June 30,				June 30,
	2021		2020		2022		2021
Assets
Current Assets
Cash and cash equivalents	$	11,889,000	$	10,479,000	$	8,153,000	$	11,889,000
Accounts receivable (net of allowances for doubtful accounts of $45,000)		17,032,000		12,941,000
Accounts receivable (net of allowances for doubtful accounts of $45,000)						21,052,000		17,032,000
Contract assets		393,000		903,000		286,000		393,000
Inventories		2,114,000		3,085,000		3,178,000		2,114,000
Prepaid expenses and other current assets		276,000		353,000		1,870,000		276,000
Income tax receivable		—		262,000
Total current assets		31,704,000		28,023,000		34,539,000		31,704,000
Property and equipment, net		3,605,000		3,788,000		4,568,000		3,605,000
Finite-life intangible assets, net		663,000		598,000		599,000		663,000
Other assets		88,000		81,000		120,000		88,000
Deferred income taxes		1,049,000		755,000		1,538,000		1,049,000
Total assets	$	37,109,000	$	33,245,000	$	41,364,000	$	37,109,000

Liabilities and Shareholders’ Equity
Current Liabilities
Current maturities of other long-term liabilities	$	33,000	$	72,000
Accounts payable		685,000		556,000	$	1,261,000	$	685,000
Accrued compensation		2,474,000		1,404,000		2,742,000		2,474,000
Income tax payable		288,000		—		51,000		288,000
Warranty reserve		940,000		740,000		1,256,000		940,000
Other accrued liabilities		219,000		214,000		1,840,000		252,000
Total current liabilities		4,639,000		2,986,000		7,150,000		4,639,000
Other long-term liabilities		54,000		9,000		41,000		54,000
Total liabilities		4,693,000		2,995,000		7,191,000		4,693,000

Commitments and Contingencies

Shareholders’ Equity
Common stock, $0.01 par value, 13,000,000 shares authorized; 8,533,209 and 8,567,834 issued and outstanding, as of June 30, 2021 and June 30, 2020, respectively		85,000		86,000
Common stock, $0.01 par value, 13,000,000 shares authorized; 8,475,438 and 8,533,209 issued and outstanding, as of June 30, 2022 and June 30, 2021, respectively						85,000		85,000
Additional paid-in capital		17,409,000		16,480,000		18,308,000		17,409,000
Retained earnings		14,922,000		13,684,000		15,780,000		14,922,000
Total shareholders’ equity		32,416,000		30,250,000		34,173,000		32,416,000
Total liabilities and shareholders’ equity	$	37,109,000	$	33,245,000	$	41,364,000	$	37,109,000

Statements of Operations

Years Ended June 30, ~~2021~~2022 and ~~2020~~2021


	Years Ended June 30,						Years Ended June 30,
	2021			2020			2022		2021
Net revenues	$	35,756,000		$	32,471,000		$	41,659,000	$	35,756,000
Cost of revenues		8,451,000			7,271,000			10,217,000		8,451,000
Gross profit		27,305,000			25,200,000			31,442,000		27,305,000

Operating expenses (income)
Operating expenses
Selling, general and administrative		22,443,000			19,945,000			27,114,000		22,443,000
Research and development		1,722,000			1,050,000			1,356,000		1,722,000
Government stimulus income		—			(913,000	)
Total operating expenses		24,165,000			20,082,000			28,470,000		24,165,000
Operating income		3,140,000			5,118,000			2,972,000		3,140,000

Interest income, net		39,000			121,000			25,000		27,000
Other expense, net		(12,000	)		—
Net income before income taxes		3,167,000			5,239,000			2,997,000		3,167,000

Income tax expense		805,000			1,078,000			692,000		805,000
Net income	$	2,362,000		$	4,161,000		$	2,305,000	$	2,362,000

Income per share:
Basic	$	0.28		$	0.50		$	0.27	$	0.28
Diluted	$	0.27		$	0.47		$	0.26	$	0.27

Weighted-average common shares outstanding:
Basic		8,566,224			8,403,220			8,471,320		8,566,224
Diluted		8,911,842			8,826,418			8,768,703		8,911,842

Electromed, Inc.

Statements of Shareholders’ Equity

Years Ended June 30, ~~2021~~2022 and ~~2020~~2021

	Common Stock											Total
	Shares		Amount			Additional Paid- in Capital			Retained Earnings			Shareholders’ Equity			Common Stock						Additional			Retained			Total Shareholders’
Balance as of June 30, 2019	8,408,351		$	84,000		$	16,128,000		$	9,523,000		$	25,735,000
															Shares			Amount			Paid-in Capital			Earnings			Equity
Balance as of June 30, 2020																8,567,834		$	86,000		$	16,480,000		$	13,684,000		$	30,250,000
Net income	—			—			—			4,161,000			4,161,000			—			—			—			2,362,000			2,362,000
Issuance of restricted stock	50,000			1,000			(1,000	)		—			—			37,090			—			—			—			—
Issuance of common stock upon exercise of options	109,483			1,000			79,000			—			80,000			32,496			—			46,000			—			46,000
Taxes paid on stock option exercised on a net basis	—			—			(628,000	)		—			(628,000	)		—			—			(141,000	)		—			(141,000	)
Share-based compensation expense	—			—			902,000			—			902,000			—			—			1,024,000			—			1,024,000
Balance as of June 30, 2020	8,567,834			86,000			16,480,000			13,684,000			30,250,000
Repurchase of common stock																(104,211	)		(1,000	)		—			(1,123,000	)		(1,124,000	)
Balance as of June 30, 2021																8,533,209			85,000			17,409,000			14,922,000			32,416,000

Net income	—			—			—			2,362,000			2,362,000			—			—			—			2,305,000			2,305,000
Issuance of restricted stock	37,090			—			—			—			—			49,400			1,000			—			—			1,000
Issuance of common stock upon exercise of options	32,496			—			46,000			—			46,000			13,245			—			—			—			—
Taxes paid on stock option exercised on a net basis	—			—			(141,000	)		—			(141,000	)		—			—			(77,000	)		—			(77,000	)
Share-based compensation expense	—			—			1,024,000			—			1,024,000			—			—			976,000			—			976,000
Repurchase of common stock	(104,211	)		(1,000	)		—			(1,123,000	)		(1,124,000	)		(120,416	)		(1,000	)		—			(1,447,000	)		(1,448,000	)
Balance as of June 30, 2021	8,533,209		$	85,000		$	17,409,000		$	14,922,000		$	32,416,000
Balance as of June 30, 2022																8,475,438		$	85,000		$	18,308,000		$	15,780,000		$	34,173,000

Electromed, Inc.

Statements of Cash Flows

Years Ended June 30, ~~2021~~2022 and ~~2020~~2021

	Years Ended June 30,
	2021			2020			Years Ended June 30,
Cash Flows From Operating Activities
							2022			2021
Cash Flows from Operating Activities
Net income	$	2,362,000		$	4,161,000		$	2,305,000		$	2,362,000
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation		477,000			619,000			503,000			477,000
Amortization of finite-life intangible assets		133,000			122,000			125,000			133,000
Share-based compensation expense		1,024,000			902,000			976,000			1,024,000
Deferred income taxes		(294,000	)		(126,000	)		(489,000	)		(294,000	)
Changes in operating assets and liabilities:
Accounts receivable		(4,091,000	)		(181,000	)		(4,020,000	)		(4,091,000	)
Contract assets		510,000			93,000			107,000			510,000
Inventories		971,000			(449,000	)		(1,072,000	)		971,000
Prepaid expenses and other assets		151,000			78,000
Income tax receivable		262,000			(262,000	)
Prepaid expenses and other current assets								(1,322,000	)		151,000
Income tax payable		288,000			(289,000	)		(237,000	)		550,000
Accounts payable and accrued liabilities		1,284,000			(472,000	)		2,170,000			214,000
Net cash provided by operating activities		3,077,000			4,196,000
Accrued compensation								268,000			1,070,000
Net cash (used in) provided by operating activities								(686,000	)		3,077,000

Cash Flows From Investing Activities
Cash Flows from Investing Activities
Expenditures for property and equipment		(287,000	)		(844,000	)		(1,425,000	)		(287,000	)
Expenditures for finite-life intangible assets		(161,000	)		(133,000	)		(100,000	)		(161,000	)
Net cash used in investing activities		(448,000	)		(977,000	)		(1,525,000	)		(448,000	)

Cash Flows From Financing Activities
Cash Flows from Financing Activities
Issuance of common stock upon exercise of options								—			46,000
Taxes paid on stock options exercised on a net basis		(141,000	)		(628,000	)		(77,000	)		(141,000	)
Issuance of common stock upon exercise of options		46,000			80,000
Repurchase of common stock		(1,124,000	)		—			(1,448,000	)		(1,124,000	)
Net cash used in financing activities		(1,219,000	)		(548,000	)		(1,525,000	)		(1,219,000	)
Net increase in cash		1,410,000			2,671,000
Net (decrease) increase in cash								(3,736,000	)		1,410,000
Cash and cash equivalents
Beginning of period		10,479,000			7,808,000			11,889,000			10,479,000
End of period	$	11,889,000		$	10,479,000		$	8,153,000		$	11,889,000

Supplemental Disclosures of Cash Flow Information

Cash paid for income taxes	$	534,000		$	1,755,000		$	1,418,000		$	534,000

Supplemental Disclosures of Noncash Investing and Financing Activities
Property and equipment acquisitions in accounts payable	$	10,000		$	1,000		$	44,000		$	10,000
Intangible asset acquisitions in accounts payable	$	42,000		$	6,000		$	3,000		$	42,000
Lease assets obtained in exchange for new operating lease liabilities	$	91,000		$	120,000		$	117,000		$	91,000

Nature of business: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were ~~approximately $658,000~~$521,000 and ~~$718,000~~$658,000 for the fiscal years ended June 30, ~~2021~~2022 (“fiscal ~~2021~~2022”) and June 30, ~~2020~~2021 (“fiscal ~~2020”~~2021”), respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

~~A summary~~Impacts of COVID-19 on the Company’s ~~significant accounting policies follows:~~business

~~Use of estimates:~~ Management uses estimates and assumptions in preparing the financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its financial statements include revenue recognition and the related estimation of variable consideration, allowance for doubtful accounts, the potential impairment of intangible and long-lived assets, inventory obsolescence, share-based compensation and the warranty reserve.

The Company did not receive any direct financial assistance from any government program during fiscal ~~2021. The Company received a one-time $913,000 payment under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)~~2021 or fiscal 2022 in ~~the fourth quarter of fiscal 2020, which partially offset lower profitability related to the revenue decline caused by the~~connection with COVID-19 pandemic during the period. The amount received from the CARES Act is subject to compliance with certain terms and conditions and reporting requirements, and such report may be audited by a federal agency for compliance with the program’s terms and conditions.relief measures.

In response to the COVID-19 pandemic and the U.S. federal government’s declaration of a public health emergency, the Centers for Medicare and Medicaid Services (“CMS”) implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health emergency. These waivers were made retroactively effective to March 1, 2020 and were in place for the duration of fiscal ~~2021.~~2021 and fiscal 2022. Clinical indications and documentation typically required were not enforced for respiratory related products including the Company’s SmartVest® Airway Clearance System (“SmartVest System”) (solely with respect to direct Medicare covered patients) applicable for the Company’s home care prescriptions. The minimum documentation now requires a valid order and documentation of a respiratory related diagnosis. Face-to-face and in-person requirements for ~~replacement~~ respiratory devices are being waived ~~during such~~while the waiver is in place. The CMS waiver was recently extended in conjunction with the extension of the federal public health emergency for an additional 90-day period ~~both of which are currently scheduled to expire in October 2021.~~beginning July 15, 2022. A temporary suspension of a 2% tax on Medicare payments was also initiated in May 2020 and ~~has been~~was extended through December 2021.

The impact of the COVID-19 pandemic on the Company’s business remains uncertain and its effects on operational and financial performance will depend in part on future developments, which cannot be reasonably estimated at this time. Such future developments include, but are not limited to, the duration, scope and severity of the COVID-19 pandemic in geographic areas in which the Company operates or in which its patients live, actions taken to contain or mitigate its impact, the impact on governmental healthcare programs and budgets, the deployment of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and evolving situation, the Company is unable to predict with confidence the likely impact of the COVID-19 pandemic on its future operations.

Use of estimates: Management uses estimates and assumptions in preparing the financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its financial statements include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation and warranty reserve.

Revenue ~~recognition:~~recognition: Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including noncash consideration, consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. See Note 2 for information on revenue.

Shipping and handling ~~expense:~~expense: Shipping and handling charges incurred by the Company are included in cost of revenues and were ~~$530,000~~$982,000 and ~~$515,000~~$530,000 for fiscal 2022 and 2021, ~~and 2020,~~ respectively.

Cash and cash ~~equivalents:~~equivalents: Cash and cash equivalents consist of cash in bank deposits and money market funds with original maturities of three months or less at the time of purchase. The Company has not experienced any losses in these accounts.

Accounts ~~receivable:~~receivable: The Company’s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors. Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid and private insurance companies. Accounts receivable are carried at amounts estimated to be received from patients under reimbursement arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition and credit history. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. The allowance for doubtful accounts was ~~approximately $45,000~~$45,000 as of June 30, ~~2021~~2022 and ~~2020.~~2021.

Contract ~~assets:~~assets: Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

~~Inventories:~~Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Work in process and finished goods are carried at standard cost, which approximates actual cost, and includes materials, labor and allocated overhead. Standard costs are reviewed at least quarterly by management, or more often in the event circumstances indicate a change in cost has occurred. The reserve for obsolescence is determined by analyzing the inventory on hand and comparing it to expected future sales. Estimated inventory to be returned is based on how many devices that have shipped that are expected to be returned prior to completion of the insurance reimbursement process.

Property and ~~equipment:~~equipment: Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. The Company retains ownership of demonstration equipment in the possession of both inside and outside sales representatives, who use the equipment in the sales process.

Finite-life intangible ~~assets:~~assets: Finite-life intangible assets include patents and trademarks. These intangible assets are amortized on a straight-line basis over their estimated useful lives, as described in Note 5.

Long-lived ~~assets:~~assets: Long-lived assets, primarily property and equipment and finite-life intangible assets, are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset or asset group may not be recoverable. In evaluating recoverability, the following factors, among others, are considered: a significant change in the circumstances used to determine the amortization period, an adverse change in legal factors or in the business climate, a transition to a new product or service strategy, a significant change in customer base, and a realization of failed marketing efforts. The recoverability of an asset or asset group is measured by a comparison of the carrying value of the asset to future undiscounted cash flows.

If the Company believes the carrying value is unrecoverable, then it recognizes an impairment charge necessary to reduce the unamortized balance to the estimated fair value of the asset or asset group. The amount of such impairment is charged to operations in the current period.

Warranty ~~liability:~~liability: The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and ~~Canada, and~~ a three-year warranty for all institutional sales and sales to individuals outside the U.S. ~~(except for Canadian home care).~~ The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is ~~shipped.~~shipped or delivered. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.

Changes in the Company’s warranty liability were ~~approximately~~ as follows:


	Years Ended June 30,						Years Ended June 30,
	2021			2020			2022			2021
Beginning warranty reserve	$	740,000		$	810,000		$	940,000		$	740,000
Accrual for products sold		354,000			79,000			494,000			354,000
Expenditures and costs incurred for warranty claims		(154,000	)		(149,000	)		(178,000	)		(154,000	)
Ending warranty reserve	$	940,000		$	740,000		$	1,256,000		$	940,000

Income ~~taxes:~~taxes: Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reverses a valuation allowance if it determines, based on the weight of all available evidence, including when cumulative losses become positive income, that it is more likely than not that some or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company recognizes tax liabilities when the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense.

Research and ~~development:~~development: Research and development costs include costs of research activities as well as engineering and technical efforts required to develop new products or make improvements to existing products. Research and development costs are expensed as incurred.

Advertising ~~costs:~~costs: Advertising costs are charged to expense when incurred. Advertising, marketing and trade show costs for fiscal 2022 and 2021 were $936,000and ~~2020 were approximately $1,062,000 and $781,000,~~$1,062,000, respectively.

Share-based ~~payments:~~payments: Share-based payment awards consist of options to purchase shares of common stock and restricted shares of common stock issued to employees for services. Expense for options is estimated using the Black-Scholes pricing model at the date of grant and expense for restricted stock is determined by the closing price on the day the grant is made. Expense is recognized on a straight-line basis over the requisite service or vesting period of the award, or at the time services are provided for non-employee awards.

Fair value of financial ~~instruments:~~instruments: The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these instruments. The carrying value of long-term debt is the remaining amount due to debtors under borrowing arrangements. To estimate the fair value of debt, the Company estimates the interest rate necessary to secure financing to replace its debt.

~~Basic and diluted earnings~~Net income per ~~share:~~common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into shares of common stock at the beginning of the period unless their effect is anti-dilutive. Common stock equivalents included in the calculation of ~~48,617~~diluted earnings per share were 297,383 and ~~zero~~345,618 shares ~~were~~for fiscal 2022 and 2021, respectively. Common stock equivalents excluded from the calculation of diluted earnings per share ~~for fiscal 2021 and 2020, respectively, as~~because their impact was ~~antidilutive. See Note 8~~anti-dilutive were 113,646 and 48,617 shares for ~~information~~fiscal 2022 and 2021, respectively.

In June 2016, the Financial Accounting Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments -- Credit Losses: Measurement of Credit Losses on ~~share-based payments.~~Financial Instruments, which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. It is effective for interim and annual reporting periods beginning after December 15, 2022, with early adoption permitted.

Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including ~~non-cash consideration,~~ consideration paid or payable tofrom customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under ~~Financial Accounting Standards Board~~ Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met.

The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the Company’s SmartVest® Airway Clearance System (“SmartVest ~~System~~System”) after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of ~~revenues.~~revenues in the Statements of Operations.

The timing of revenue recognition, billings and cash collections results in accounts receivable on the ~~balance sheets~~Balance Sheets as further described below under Accounts receivable and Contract assets.

Disaggregation of revenues. In the following table, revenue is disaggregated by market:

	Fiscal Year Ended June 30,				Years Ended June 30,
	2021		2020		2022		2021
Commercial	$	12,530,000	$	11,728,000	$	14,904,000	$	12,530,000
Medicare		19,044,000		14,863,000		21,144,000		19,044,000
Medicaid		846,000		1,696,000		1,045,000		846,000
Other		566,000		1,036,000		911,000		566,000
Total	$	32,986,000	$	29,323,000	$	38,004,000	$	32,986,000

Revenues in the Company’s home care, home care distributor and international markets are recognized at a point in time when control passes to the customer upon product shipment or delivery. Revenues in the Company’s institutional market include sales recognized at a point in time upon shipment or delivery as well as revenues recognized over time under operating leases.

Performance obligations and transaction price. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below:

Home care market. In the Company’s home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised of three main components - a generator, a vest and a connecting hose - that are sold together as an integrated unit. Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.

The Company makes available to its home care patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation: the SmartVest System.

Home care patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System.

Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long-standing business practice to regard all home care agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies. As a result, the Company’s product sales qualify for point in time revenue recognition. Control transfers to the patient, and revenue is recognized, upon shipment or delivery of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivableand Contract assets below.

The Company’s contractually stated transaction prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments.

Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information including historical collection patterns to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, claims in appeals with Medicare and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

For ~~example, for~~ contracts in which the Company believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal.

For each type of variable consideration discussed above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.

The Company often receives payment from third-party payers for the SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs, the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time.

Home ~~Care Distributors.~~ care distributors. Sales to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor’s purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to the distributor as applicable.

Institutional market. The Company’s institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:

International market. Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery to the distributor as applicable.

Product ~~Warranty.~~warranty. The Company offers warranties on its products. These warranties are assurance type warranties not sold on a standalone basis or are otherwise considered immaterial in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. ~~From time to time the Company will provide accessory parts at its discretion at no cost to the customer.~~

Accounts receivable. The Company’s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors. Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid and private insurance companies. Accounts receivable ~~include~~are carried at amounts ~~billed~~estimated to ~~customers~~be received from patients under reimbursement arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and ~~third-party payers, for which only the passage of time is required before payment of consideration is due. Amounts due~~considering a customer’s financial condition and credit history. Receivables are ~~stated at their net estimated realizable value.~~written off when deemed uncollectible.

Contract assets. Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts ~~will~~is expected to turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

~~Incremental costs to obtain a contract.~~ Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expense sales incentives as incurred. These costs are included in selling, general and administrative expenses in the Company’s statements of operations.

Contract balances. The following table provides information about accounts receivable and contracts assets from contracts with customers:


					June 30,
	June 30, 2021		June 30, 2020		2022		2021
Receivables, included in “Accounts receivable, net of allowance for doubtful accounts”	$	17,032,000	$	12,941,000	$	21,052,000	$	17,032,000
Contract assets	$	393,000	$	903,000
Contract Assets					$	286,000	$	393,000

Schedule of ~~June 30, 2021 and 2020 were approximately as follows:~~components of inventories


	June 30,						June 30,
	2021			2020			2022			2021
Parts inventory	$	1,779,000		$	2,271,000		$	2,672,000		$	1,779,000
Work in process		23,000			127,000			100,000			23,000
Finished goods		445,000			827,000			469,000			445,000
Estimated inventory to be returned		167,000			150,000			228,000			167,000
Less: Reserve for obsolescence		(300,000	)		(290,000	)		(291,000	)		(300,000	)
Total	$	2,114,000		$	3,085,000		$	3,178,000		$	2,114,000

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was ~~approximately $1,248,000~~$433,000 and ~~$1,119,000~~$1,248,000 as of June 30, 2022 and 2021, ~~and 2020,~~ respectively.

The activity and net balances of finite-life intangible assets were ~~approximately~~ as follows:

Based on the carrying value as of June 30, ~~2021,~~2022, future amortization is expected to be ~~approximately~~ as follows:


Fiscal years ending June 30:
2022	$	102,000
2023		41,000	$	46,000
2024		36,000		42,000
2025		34,000		40,000
2026		34,000		39,000
2027				38,000
Thereafter		416,000		394,000
Total	$	663,000	$	599,000

The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December ~~16, 2020,~~17, 2021, the Company renewed its ~~$2,500,000~~$2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of June 30, ~~2021~~2022 or June 30, ~~2020.~~2021. Interest on borrowings under the line of credit, if any, accrues at the prime rate ~~(3.25%~~(4.75% as of June 30, ~~2021)~~2022) less ~~1.00%~~1.0% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of ~~$2,500,000~~$2,500,000 or ~~57.00%~~57.0% of eligible accounts receivable and the line of credit expires on December 18, ~~2021,~~2023, if not ~~renewed. As of~~renewed before such date. At June 30, ~~2021,~~2022, the maximum ~~$2,500,000~~$2,500,000 was eligible for borrowing. ~~The~~Payment obligations under the line of credit, isif any, are secured by a security interest in substantially all of the tangible and intangible assets of the Company.

The documents governing the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than ~~$10,125,000~~$10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Authorized shares: The Company’s Articles of Incorporation, as amended, have established 15,000,000 authorized shares of capital stock consisting of 13,000,000 shares of common stock, par value ~~$0.01~~$0.01 per share, and 2,000,000 shares of undesignated stock.

On May 26, 2021 the Company’s Board of Directors (the “Board”) approved a stock repurchase authorization. Under the authorization, the Company ~~may~~was originally able to repurchase up to ~~$3.0~~$3.0 million of shares of common stock through May 26, 2022. On May 26, 2022, our Board of Directors removed the date limitation. As of June 30, ~~2021,~~2022, a total of ~~104,211~~120,416 shares have been repurchased and retired under this authorization for a total cost of ~~$1,124,000,~~$1,448,000, or ~~$10.79~~$12.02 per share. ~~As of June 30, 2021, there were an additional $1,876,000 of shares of common stock available to be repurchased by the Company under the authorization.~~ Repurchased shares have been retired and constitute authorized but unissued shares.

Share-based compensation expense for fiscal 2022 and 2021 was $976,000and ~~2020 was approximately $1,024,000 and $902,000,~~$1,024,000, respectively, related to employee stock options and restricted stock awards. This expense is included in selling, general and administrative expense in the Statements of Operations. As of June 30, ~~2021,~~2022, the Company had ~~approximately $553,000~~$460,000 of unrecognized compensation expense related to non-vested equity awards, which is expected to be recognized over a weighted-average period of ~~0.9 years.~~1.5 to 2.0 years related to restricted stock awards and employee stock options, respectively.

Employee options: The Company has historically granted stock options to employees as long-term incentive compensation. Options expire ten years from the grant date and vest over a period of three years. In November 2017, the Company’s shareholders approved the 2017 Omnibus Incentive Plan (the “2017 Plan”) which supersedes the 2014 Equity Incentive Plan (the “2014 Plan”). The 2017 Plan allows the Board to grant stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards, as well as cash incentive awards to all employees, non-employee directors, and advisors or consultants of the Company. The vesting schedule and term for each award are determined by the Board upon each grant. Upon vesting, and the Company’s determination that any necessary conditions precedent to the exercise of shares (such as satisfaction of tax withholding and compliance with applicable legal requirements) have been satisfied, shares purchased are delivered to the participant in a manner prescribed or permitted by the Board. The maximum number of shares of common stock available for issuance under the 2017 Plan is ~~900,000.~~900,000. There were ~~258,500~~248,500 options granted under the 2014 Plan and prior plans outstanding as of June 30, ~~2021.~~2022. There were ~~209,549~~253,584 options issued under the 2017 Plan outstanding and ~~476,224~~370,789 shares available for grant under the 2017 Plan as of June 30, ~~2021.~~2022.

The Company recognizes compensation expense related to share-based payment transactions in the financial statements based on the estimated fair value of the award issued. The fair value of each option is estimated using the Black-Scholes pricing model at the time of award grant. The Company estimates the expected life of options based on the expected holding period by the option holder. The risk-free interest rate is based upon observed U.S. Treasury interest rates for the expected term of the options. The Company makes assumptions with respect to expected stock price volatility based upon the historical volatility of its stock price. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates. Forfeitures are estimated based on the percentage of awards expected to vest, taking into consideration the seniority level of the award recipient.accounted for as they occur.

The following assumptions were used to estimate the fair value of options granted:

	Years Ended June 30,						Years Ended June 30,
	2021			2020			2022			2021
Risk-free interest rate		0.31-0.59	%		1.85	%		0.89-2.52	%		0.31-0.59	%
Expected term (years)		6			6			6			6
Expected volatility		283-335	%		190	%		55-64	%		283-335	%

During the year ended June 30, 2022, the Company had a change in estimate related to its expected volatility used to estimate the fair value of options granted. The change had no impact on the Financial Statements. The following table presents employee stock option activity for fiscal ~~2021~~2022 and ~~2020:~~2021:

	Number of Shares			Weighted- Average Grant Date Fair Value		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in Years)	Number of Shares			Weighted- Average Grant Date Fair Value		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in Years)
Options outstanding as of June 30, 2019		683,000		$	3.35	$	3.84	6.96
Options outstanding as of June 30, 2020										590,780		$	3.96	$	4.34		6.87
Granted		149,300		$	5.19	$	5.29	—		61,017		$	14.13	$	14.14		—
Exercised		(194,670	)	$	2.47	$	3.08	—		(71,150	)	$	4.78	$	5.09		—
Canceled or Forfeited		(46,850	)	$	5.16	$	5.34	—
Options outstanding as of June 30, 2020		590,780		$	3.96	$	4.34	6.87
Canceled or forfeited										(112,598	)	$	6.24	$	6.50		—
Options outstanding as of June 30, 2021										468,049		$	4.61	$	4.98		5.82
Options exercisable as of June 30, 2021										442,437		$	4.16	$	4.54		5.64

Granted		61,017		$	14.13	$	14.14	—		81,901		$	6.63	$	11.52		—
Exercised		(71,150	)	$	4.78	$	5.09	—		(32,000	)	$	3.70	$	5.44		—
Canceled or Forfeited		(112,598	)	$	6.24	$	6.50	—
Options outstanding as of June 30, 2021		468,049		$	4.61	$	4.98	5.82
Options exercisable as of June 30, 2021		442,437		$	4.16	$	4.54	5.64
Canceled or forfeited										(15,866	)	$	6.63	$	11.30		—
Options outstanding as of June 30, 2022										502,084		$	3.71	$	5.82		5.35
Options exercisable as of June 30, 2022										429,888		$	3.16	$	4.77		4.76

The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds its exercise price. ~~As of~~At June 30, ~~2021,~~2022, the weighted average remaining contractual term for all outstanding stock options was ~~5.8~~5.4 years and their aggregate intrinsic value was ~~$3,094,000.~~$2,244,000. Outstanding ~~as of~~at June 30, ~~2021~~2022 were ~~468,049~~502,084 stock options issued to employees, of which ~~442,437~~429,888 were vested and exercisable and had an aggregate intrinsic value of ~~$3,074,000.~~$2,244,000.

Restricted stock: The 2017 Plan permits the Personnel and Compensation Committee of the Board to grant other stock-based awards, including shares of restricted stock. The Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years following the applicable grant date.

The Company issued restricted stock awards to employees totaling ~~30,756~~31,400 and ~~35,000~~30,756 during fiscal ~~2021~~2022 and ~~2020,~~2021, respectively, with a vesting term of one to three years and a fair value of ~~$14.68~~$11.48 and ~~$5.84~~$14.68 per share, respectively. During fiscal ~~2021~~2022 and ~~2020,~~2021, the Company issued restricted stock awards to directors totaling 18,000 each year, with a vesting term of six months and a fair value of ~~$9.94~~$12.09 and ~~$9.74~~$9.94 per share for fiscal 2022 and 2021,respectively. Restricted stock transactions during the years ended June 30, ~~2021~~2022 and ~~2020~~2021 are summarized as follows:

	Shares of Restricted Stock			Weighted-Average Grant Date Fair Value per Share		Shares of Restricted Stock			Weighted-Average Grant Date Fair Value per Share
Outstanding as of June 30, 2019		29,998		$	5.46
Granted		53,000		$	7.17
Vested		(45,833	)	$	6.83
Forfeited		(14,666	)	$	6.23
Outstanding as of June 30, 2020		22,499		$	6.19		22,499		$	6.19
Granted		48,756		$	12.93		48,756		$	12.93
Vested		(40,752	)	$	9.47		(40,752	)	$	9.47
Outstanding as of June 30, 2021		30,503		$	12.57		30,503		$	12.57
Granted							49,400		$	11.70
Vested							(45,219	)	$	11.61
Outstanding as of June 30, 2022							34,684		$	12.59

Components of the provision for income taxes ~~for fiscal 2021 and 2020~~ were as follows:


	Years Ended June 30,						Years Ended June 30,
	2021			2020			2022			2021
Current:
Current Federal	$	861,000		$	922,000		$	891,000		$	861,000
Current State		238,000			282,000			290,000			238,000
Total Current		1,099,000			1,204,000			1,181,000			1,099,000
Deferred:
Deferred Federal		(204,000	)		(70,000	)		(348,000	)		(204,000	)
Deferred State		(90,000	)		(56,000	)		(141,000	)		(90,000	)
Total Deferred		(294,000	)		(126,000	)		(489,000	)		(294,000	)

Total Income Tax Expense	$	805,000		$	1,078,000		$	692,000		$	805,000

The total income tax expense differed from the expected tax expense, computed by applying the federal statutory rate to the Company’s pretax income, as follows:

The effective tax rates for fiscal 2022 and 2021 were 23.1% and ~~2020 were 25.4% and 20.6%~~25.4%, respectively.


	June 30,						June 30,
	2021			2020			2022			2021
Deferred tax assets (liabilities):
Revenue recognition and accounts receivable reserves	$	655,000		$	468,000		$	917,000		$	655,000
Accrued liabilities		297,000			253,000			325,000			297,000
Property and equipment		(218,000	)		(202,000	)		(246,000	)		(218,000	)
Finite-life intangible assets		(15,000	)		(6,000	)		(41,000	)		(15,000	)
Stock options		414,000			458,000			532,000			414,000
Tax credits		125,000			92,000			152,000			125,000
Accounting method change		(140,000	)		(282,000	)		—			(140,000	)
Valuation allowance on deferred taxes		(125,000	)		(91,000	)		(152,000	)		(125,000	)
Other		56,000			65,000			51,000			56,000
Net deferred tax assets	$	1,049,000		$	755,000		$	1,538,000		$	1,049,000

The Company has state tax credits of ~~$125,000,~~$152,000, net of federal taxes, which if unused, will begin to expire in calendar ~~years 2026 and 2034.~~year 2026. The Company has taken a full valuation allowance against these credits which relate to research and development tax credits in Minnesota, a state in which the Company has a low state apportionment factor.

The Company applies the accounting standard for uncertain tax positions pursuant to which a more-likely-than-not threshold is utilized to determine the recognition and derecognition of uncertain tax positions. Once the more-likely-than-not threshold is met, the amount of benefit to be recognized is the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement. It further requires that a change in judgment related to the expected ultimate resolution of uncertain tax positions be recognized in earnings in the period of such a change. The Company does not have any uncertain tax positions as of June 30, ~~2021~~2022 and June 30, ~~2020.~~2021.

The Company is subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. With limited exceptions, tax years prior to the Company’s fiscal year ended June 30, ~~2018~~2019 are no longer open to federal, state and local examination by taxing authorities. The Company’s examination by the Internal Revenue Service (the “IRS”) for the fiscal year ended June 30, 2020 is complete and the IRS has no findings. The Company is not under any current income tax examinations by any other state or local taxing authority. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

The Company has ~~six~~ leases for office and warehouse space and office equipment that require monthly payments. These leases have ~~escalating~~ payments ranging from ~~approximately $200~~$200 to ~~$4,400~~$4,700 per month which expire through ~~January 2026~~December 2025 and are recognized on a straight-line basis over the life of the lease. ~~The Company has a lease for office equipment that requires payments of approximately $1,600 per month through August 2022.~~ All leases are classified as operating leases which do not include renewal options. The Company currently does not have any short-term or variable lease costs. The Company ~~applied~~elected the practical expedient to calculate the present value of the fixed payments without having to perform an allocation to lease and non-lease components.

The Company has recognized right of use assets associated with its operating leases of ~~approximately $88,000~~$120,000 and ~~$81,000~~$88,000 as of June 30, ~~2021~~2022 and June 30, ~~2020,~~2021, respectively, which is included in other assets on the Company’s balance sheet. Operating lease liabilities were ~~$87,000~~$120,000 and ~~$81,000~~$87,000 as of June 30, ~~2021~~2022 and June 30, ~~2020,~~2021, respectively, which are included in ~~current maturities of long-term~~other accrued liabilities and other long-term liabilities on the Company’s balance sheet.

As of June 30, ~~2021,~~2022, the Company has a weighted-average lease term of ~~2.8~~1.1 years for its operating leases, which have a weighted-average discount rate of ~~4.0%~~4.0%. Operating lease payments of ~~$74,000~~$94,000 are included in operating cash flows in fiscal ~~2021.~~ 2022.

Maturities of lease liabilities, which are included in ~~current maturities of long-term~~other accrued liabilities and other long-term liabilities on the ~~Company’s balance sheet,~~Balance Sheet, are as follows:

Fiscal years ending June 30:
2022	$	29,000
2023		18,000		$	81,000
2024		17,000			17,000
2025		17,000			17,000
2026		8,000			9,000
Total lease payments		89,000			124,000
Less: Interest		(2,000	)		(4,000	)
Present value of lease liabilities	$	87,000		$	120,000

Litigation: The Company ~~may~~is occasionally ~~be party to actions, proceedings,~~involved in claims orand disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other disposition.

On September 8, 2021 a state court putative class action lawsuit was filed in Minnesota against the Company asserting injury resulting from the previously announced data breach that impacted the Company’s customer protected health information and employee personal information and seeking compensatory damages, equitable relief, and attorneys’ fees and costs. On October 6, 2021, the proceeding was removed to the District of Minnesota. The Company believes the plaintiff was not injured as a result of the data privacy incident, and, as a result, the claims are without merit. Accordingly, on November 11, 2021, the Company moved to dismiss the complaint in its entirety. Prior to the hearing on the motion to dismiss, the parties agreed in principal to settle the case. The parties are continuing to negotiate the settlement agreement and expect to submit a motion to settle the class action in the near future. If the parties are unable to agree to the settlement terms or, if the Court does not grant the motion for settlement, the Company will continue to vigorously defend the lawsuit; however, at this time, the Company is unable to determine the ultimate outcome or potential exposure to loss, if any.

401(k) Profit Sharing Plan: The Company has an employee benefit plan under Section 401(k) of the Internal Revenue Code covering all employees who are 21 years of age or older and have at least 1,000 hours of service with the Company. The Company matches each employee’s salary reduction contribution, not to exceed four percent of annual compensation. Total employer contributions to this plan for fiscal 2022 and 2021 were $461,000and ~~2020 were approximately $399,000 and $329,000,~~$399,000, respectively.

Employment Agreements: The Company has entered into formal employment agreements with its President and Chief Executive Officer, its Interim Chief Financial Officer, and its Chief ~~Financial~~Commercial Officer, as amended from time to time. These agreements provide these officers with, among other things, twelve to eighteen months of base salary upon a termination without “Cause” or in the event the employee resigns for “Good Reason” or within twelve months of a “Change in Control,” as such terms are defined in the respective employment agreements.

The Company uses a parts supplier whose founder and president was a director of the Company through November 12, 2021. The Company made payments to the supplier of $360,000 and $1,000 during fiscal year 2022 and 2021, respectively. Amounts due to the supplier at June 30, 2022 were $160,000, which were included in accounts payable on the Balance Sheets. There was no amount due to the supplier at June 30, 2021.

The Company evaluates, as of each reporting period, events or transactions that occur after the balance sheet date through the date the financial statements are issued for either disclosure or adjustment to the Company’s financial results. Except as described below, there have been no events subsequent to June 30, 2022 which would require recognition in the Financial Statements or Notes to the Financial Statements.

Michael J. MacCourt, the Company’s former Chief Financial Officer, Treasurer and Secretary, ceased to serve in those positions effective July 1, 2022 at which time the Company terminated its formal employment agreement with Mr. MacCourt.

~~Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.~~

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, as of the end of the period subject to this Annual Report on Form 10-K. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting refers to the process designed by, or under the supervision of, our President and Chief Executive Officer and our Chief Financial Officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

(1) Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

(2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting cannot provide absolute assurance of preventing and detecting misstatements on a timely basis. It is possible to design into the process safeguards to reduce, though not eliminate, the risk that misstatements are not prevented or detected on a timely basis. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company.

Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in the report entitled Internal Control-Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. Based on this assessment, management has concluded that, as of June 30, ~~2021,~~2022, our internal control over financial reporting was effective.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to the rules of the SEC that exempt smaller reporting companies from the auditor attestation requirement.

There were no changes in our internal control over financial reporting that occurred during the fourth quarter of fiscal ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Certain information required by Part III is incorporated by reference from our definitive Proxy Statement for the Fiscal ~~2021~~2023 Annual Meeting of Shareholders (the “Proxy Statement”). Except for those portions specifically incorporated in this Annual Report on Form 10-K by reference to the Proxy Statement, no other portions of the Proxy Statement are deemed to be filed as part of this Annual Report on Form 10-K.

The following sets forth certain information about our current executive officers:

Kathleen S. Skarvan, age ~~65,~~66, joined Electromed in December 2012 as Chief Executive Officer, became a director in November 2013 and was appointed to the additional position of President in August 2015. Ms. Skarvan served as Vice President of Operations at OEM Fabricators from November 2011 until October 2012. Prior to her position with OEM Fabricators, Ms. Skarvan served in various roles at Hutchinson Technology Incorporated, most recently as the President of the Disk Drive Components Division from April 2007 until March 2011. As President of the Disk Drive Components Division, Ms. Skarvan managed a public company division with annual revenues in excess of $300 million. Ms. Skarvan also served as a Senior Vice President of Hutchinson Technology Incorporated from December 2010 to March 2011, and as Vice President of Sales & Marketing of the Disk Drive Components Division from October 2003 until April 2007. She has served on the Board of Trustees of the St. Cloud State University Foundation since June 2015. Ms. Skarvan has a bachelor’s degree from St. Cloud State University.

~~Michael J. MacCourt~~Michelle C. Wirtz, , age ~~43,~~39, joined Electromed in ~~May 2020~~December 2021 as the Company’s Corporate Controller and has served as Electromed’s Interim Chief Financial Officer, Treasurer and Secretary, since June 1, 2022. Prior to joining Electromed, she served as Corporate Controller at Icario, Inc. from June 2018 to December 2021. She was a senior consultant at Salo LLC from 2016 to June 2018. She began her career in accounting, serving in various roles focused on the life sciences industry at McGladrey & Pullen LLP (now RSM US LLP) and Ernst & Young Global Limited. Ms. Wirtz graduated from North Dakota State University with a degree in Accounting and holds an active Certified Public Accountant (CPA) license in the State of Minnesota.

Christopher G. Holland, age 53, joined Electromed in February 2022 as the Company’s Chief Commercial Officer. Prior to joining Electromed, Mr. Holland was the Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., a Medical Device manufacturer of a mandibular advancement device for sleep apnea where he ~~served as~~led new product introduction and revenue-growth initiatives across the ~~Senior Director of Commercial Finance at Starkey Hearing Technologies, a large private hearing aid manufacturer,~~enterprise, from August 2021 to February 2022. Prior to his time at Prosomnus, from 2008 to 2020, Mr. Holland served in various positions at Nonin Medical, Inc., a producer of noninvasive pulse oximeters, regional oximeters, and capnographs, including most recently as Executive Vice President, Sales & Global Development from January 2019 ~~until May 2020. He was responsible for partnering with Starkey’s senior leadership team~~ to ~~develop~~July 2020, and ~~execute the company’s commercial strategy. Previously, he spent more than nine years at Medtronic in roles of increasing responsibility, concluding with his service~~ as ~~Divisional~~ Chief ~~Financial~~Commercial Officer ~~of the Lung Health business~~and Senior Vice President Global Sales, Marketing, Business Development from ~~May~~ 2015 to ~~August 2019. Mr. MacCourt also has an extensive consulting background primarily at PricewaterhouseCoopers, where he held management roles~~July 2020 Earlier in ~~both financial process improvement and business analytics. Mr. MacCourt started~~ his career, Holland held various leadership roles at ~~Procter & Gamble~~Cisco Systems and ~~then ConAgra Foods, where he held Financial Analyst, Cost Analyst and Business Analyst positions.~~PriceWaterhouseCoopers. Mr. ~~MacCourt~~Holland graduated from ~~Drake~~Minnesota State University with a ~~joint~~ degree in ~~Accounting/Finance,~~Computer Science/Math (minor) and isobtained a ~~Certified Public Accountant (CPA), a CFA charterholder, and a Certified~~Master in Business Administration (MBA) with Distinction from Jack Welch Management ~~Accountant (CMA).~~Institute – Strayer University.

Our Board annually reviews and approves revisions to our Code of Ethics and Business Conduct (the “Code of Ethics”) that applies to all employees, directors, and officers, including the Chief Executive Officer and the Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer). The Code of Ethics was updated in May 2020 and is available in the “Investor Relations” section of our website at www.smartvest.com. We intend to disclose on our website any amendment to or waiver from any provision of the Code of Ethics that applies to our Chief Executive Officer or our Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), and that relates to any element of the Code of Ethics identified in Item 406(b) of Regulation S-K, as promulgated by the SEC. Such disclosure will be provided promptly following the date of the amendment or waiver.

The additional information required by this item is incorporated herein by reference to the sections labeled “Election of Directors,” “Corporate Governance,” “and “Security Ownership Certain Beneficial Owners and Management” and, if any, under “Delinquent Section 16(a) Reports” in the Proxy Statement.

The information required by this item is incorporated herein by reference to the sections labeled “Executive Compensation,” “Director Compensation,” and “Corporate Governance – Personnel and Compensation Committee” in the Proxy Statement.

~~Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.~~

The information required by this item relating to the security ownership of certain holders is incorporated herein by reference to the sections labeled “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in the Proxy Statement.

~~Item 13. Certain Relationships and Related Transactions, and Director Independence.~~

The information required by this item is incorporated herein by reference to the sections labeled “Corporate Governance–Independence” and “Related Person Transaction Approval Policy” in the Proxy Statement.

~~Item 14. Principal Accountant Fees and Services.~~Our independent registered public accounting firm is RSM US LLP, Rochester, MN, Auditor firm ID: 49.

The information required by this item is incorporated herein by reference to the section labeled “Ratification of the Appointment of the ~~Company’s~~Company's Independent Registered Public Accounting Firm –- Audit Fees” in the Proxy Statement.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Minnesota	41-1732920
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification No.)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value ~~$0.01~~ $0.01 per share		ELMD		NYSE American

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐
~~Non-accelerated filer ☐~~	Smaller reporting company ☑ Emerging growth company ☐

Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
April 1 to April 30, 2022	1,253	$	12.53		1,253	$	898,000
May 1 to May 31, 2022	28,126	$	12.33		28,126	$	551,000
June 1 to June 30, 2022	10,799	$	11.48		10,799	$	427,000
Total	40,178	$	12.10		40,178

Report of Independent Registered Public Accounting Firm	F-2

Balance Sheets	F-4

Statements of Operations	F-5

Statements of Shareholders’ Equity	F-6

Statements of Cash Flows	F-7

Notes to Financial Statements	F-8

	Electromed, Inc.
	(Exact Name of Registrant as Specified in its Charter)

	~~(952)~~ (952) 758-9299
	(Registrant’s telephone number, including area code)

PART I		1
Item 1.	Business	1
Item 1A.	Risk Factors	13
Item 1B.	Unresolved Staff Comments	13
Item 2.	Properties	13
Item 3.	Legal Proceedings	13
Item 4.	Mine Safety Disclosures	13

PART II		13
Item 5.	Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	13
Item 6.	~~Selected Financial Data~~[Reserved]	14
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 8.	Financial Statements and Supplementary Data	F-1
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	23
Item 9A.	Controls and Procedures	23
Item 9B.	Other Information	23
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	24

PART III		24
Item 10.	Directors, Executive Officers and Corporate Governance	24
Item 11.	Executive Compensation	24 25
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	25
Item 13.	Certain Relationships and Related Transactions, and Director Independence	25
Item 14.	Principal Accountant Fees and Services	25

PART IV		25
Item 15.	Exhibits and Financial Statement Schedules	25
Item 16.	Form 10-K Summary	27

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
April 1 to April 30, 2021	—		$	—	—		$	—
May 1 to May 30, 2021	—		$	—	—		$	—
June 1 to June 30, 2021		104,211	$	10.79		104,211	$	1,876,000
Total		104,211	$	10.79		104,211	$	1,876,000

	Year Ended June 30, 2022			Year Ended June 30, 2021
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	393,000		$	903,000
Reclassification of contract assets to accounts receivable		(833,000	)		(1,551,000	)
Contract assets recognized		784,000			1,060,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(58,000	)		(19,000	)
Contract assets, ending	$	286,000		$	393,000

	Fiscal Year Ended			Fiscal Year Ended
	June 30, 2021			June 30, 2020
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	903,000		$	996,000
Reclassification of contract assets to accounts receivable		(1,551,000	)		(1,858,000	)
Contract assets recognized		1,060,000			1,734,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(19,000	)		31,000
Contract assets, ending	$	393,000		$	903,000

	Estimated Useful		June 30,
	Lives (Years)		2021			2020
Building and building improvements		15-39	$	3,446,000		$	3,437,000
Land		N/A		200,000			200,000
Land improvements		15		166,000			166,000
Equipment		3-7		3,467,000			3,311,000
Demonstration and rental equipment		3		1,060,000			1,075,000
Construction in progress		N/A		26,000			16,000
				8,365,000			8,205,000
Less: Accumulated depreciation				(4,760,000	)		(4,417,000	)
Net property and equipment			$	3,605,000		$	3,788,000

	Estimated Useful Lives	June 30,
	(Years)	2022			2021
Building and building improvements	15-39	$	3,420,000		$	3,446,000
Land	N/A		200,000			200,000
Land improvements	15		162,000			166,000
Equipment	3-10		2,752,000			3,467,000
Demonstration and rental equipment	3		1,036,000			1,060,000
Construction in progress	N/A		957,000			26,000
			8,527,000			8,365,000
Less: Accumulated depreciation			(3,959,000	)		(4,760,000	)
Net property and equipment		$	4,568,000		$	3,605,000

Exhibit Number	Description
~~Number~~	~~Description~~	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference
3.2	Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)	Incorporated by Reference
4.1	Description of Securities (incorporated by reference to Exhibit 4.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2019)	Incorporated by Reference
10.1	Electromed, Inc. 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 15, 2011)*	Incorporated by Reference
10.2	Form of Stock Option Award Agreement under the Electromed, Inc. 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q for the quarter ended December 31, 2011)*	Incorporated by Reference
10.3	Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.4	Form of Incentive Stock Option Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference

~~Exhibit~~
~~Number~~	~~Description~~	~~Method of Filing~~
10.5	Form of Nonqualified Stock Option Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.6	Form of Restricted Stock Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.7	Electromed, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to Registration Statement on Form S-8 filed December 4, 2017)*	Incorporated by Reference
10.8	Form of Restricted Award Agreement under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-K for the fiscal year ended June 30, 2018)*	Incorporated by Reference
10.9	Form of Non-Qualified Option Agreement under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended March 31, 2019)*	Incorporated by Reference
10.10	Form of Restricted Stock Agreement (Non-Employee Directors) under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.13 to Annual Report on Form 10-K for the fiscal year ended June 30, 2018)*	Incorporated by Reference
10.11	Non-Competition, Non-Solicitation and Confidentiality Agreement with Kathleen S. Skarvan dated effective December 1, 2012 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed December 3, 2012)*	Incorporated by Reference
10.12	Non-Competition, Non-Solicitation and Confidentiality Agreement with Michelle C. Wirtz dated effective December 20, 2021*	Filed electronically
10.13	Non-Competition, Non-Solicitation and Confidentiality Agreement with Christopher G. Holland dated effective February 16, 2022*	Filed electronically
10.14	Amended and Restated Employment Agreement with Kathleen S. Skarvan dated as of December 2, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed December 6, 2019)*	Incorporated by Reference
~~10.13~~10.15	Employment Agreement with ~~Michael J. MacCourt~~Michelle C. Wirtz dated ~~as of May 7, 2020~~February 21, 2022 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed ~~May 18, 2020)~~June 7, 2022)*	Incorporated by Reference

Exhibit Number	Description	Method of Filing
~~10.14~~10.16	Amendment to Employment Agreement with Michelle C. Wirtz, dated June 1, 2022 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed June 7, 2022)*	Incorporated by Reference
10.17	Employment Agreement with Christopher G. Holland dated February 16, 2022 (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed May 10, 2022)*	Incorporated by Reference
10.18	Business Loan Agreement with Choice Financial Group, dated December 18, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed December 17, 2019)	Incorporated by Reference
~~10.15~~10.19	Rider to Business Loan Agreement (Asset Based) with Choice Financial Group, dated December 18, 2019 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed December 17, 2019)	Incorporated by Reference
~~10.16~~10.20	Rider to Business Loan Agreement (Asset Based) with Choice Financial Group, dated December 16, 2020 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed December 17, 2020)	Incorporated by Reference
10.21	Rider to Business Loan Agreement (Asset Based) with Choice Financial Group, Dated December 17, 2021 (incorporated by reference to Exhibit 10. 1 to Current Report on 8-K filed December 17, 2021)	Incorporated by Reference
~~10.17~~10.22	Cooperation Agreement, dated July 25, 2022, by and among Electromed, Inc. and Summers Value Partners LLC and certain of its affiliates signatory thereto (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed July 25, 2022)	Incorporated by Reference
10.23	Description of Fiscal Year ~~2021~~2022 Officer Bonus Plan (incorporated by reference to Exhibit ~~10.21~~10.17 to Annual Report on Form 10-K for the fiscal year ended June 30, ~~2020)~~2021)*	Incorporated by Reference
~~10.18~~10.24	Description of Fiscal Year ~~2022~~2023 Officer Bonus Plan*	Filed Electronically
23.1	Consent of Independent Registered Public Accounting Firm	Filed Electronically
24.1	Powers of Attorney	Filed Electronically
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	~~Filed~~Furnished Electronically
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	~~Filed~~Furnished Electronically
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed Electronically

~~Exhibit~~
~~Number~~101.DEF	~~Description~~	~~Method of Filing~~
~~101.DEF~~	XBRL Taxonomy Extension Definition Linkbase	Filed Electronically
101.INS	XBRL Instance Document	Filed Electronically
101.LAB	XBRL Taxonomy Extension Label Linkbase	Filed Electronically
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	Filed Electronically
101.SCH	XBRL Taxonomy Extension Schema	Filed Electronically
104	Cover Page Interactive Data File (embedded within the inline XBRL Document)	Filed electronically

		ELECTROMED, INC.

Date: August 23, 2022	By	/s/ Kathleen S. Skarvan
			~~ELECTROMED, INC.~~Kathleen S. Skarvan

~~Date: August 24, 2021~~	By	~~/s/ Kathleen S. Skarvan~~
		~~Kathleen S. Skarvan~~
		President and Chief Executive Officer


Signature	Title	Date

/s/ Kathleen S. Skarvan	President, Chief Executive Officer and Director	August ~~24, 2021~~ 23, 2022
Kathleen S. Skarvan	(principal executive officer)

/s/ ~~Michael J. MacCourt~~ Michelle C. Wirtz	Interim Chief Financial Officer	August ~~24, 2021~~ 23, 2022
~~Michael J. MacCourt~~ Michelle C. Wirtz	(principal financial and accounting officer)

*	Chairman and Director	August ~~24, 2021~~ 23, 2022
~~Stephen H. Craney~~ Lee A. Jones

*	Director	August ~~24, 2021~~ 23, 2022
Stan K. Erickson

*	Director	August ~~24, 2021~~ 23, 2022
Gregory J. Fluet

*	Director	August ~~24, 2021~~ 23, 2022
~~Lee A. Jones~~ Joseph L. Galatowitsch

*	Director	August ~~24, 2021~~ 23, 2022
Andrea M. Walsh

*	Director	August ~~24, 2021~~ 23, 2022
~~George H. Winn~~ Kathleen A. Tune

*	Director	August 23, 2022
Andrew J. Summers

	By	~~/s/~~ /s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		Attorney-in-Fact